Photo credits: Shuan Ji, Principal Scientist, Cambridge, Sanofi US - @Zoe Savitz Exhibit 99.1 Exhibit 99.1 TABLE OF CONTENTS Condensed half-year consolidated financial statements 2 Consolidated balance sheets - assets 2 Consolidated balance sheets…
Photo credits: Shuan Ji, Principal Scientist, Cambridge, Sanofi US - @Zoe Savitz
Exhibit 99.1
Exhibit 99.1
TABLE OF CONTENTS
- Condensed half-year consolidated financial statements
2
Consolidated balance sheets - assets
2
Consolidated balance sheets - equity and liabilities
3
Consolidated income statements
4
Consolidated statements of comprehensive income
5
Consolidated statements of changes in equity
6
Consolidated statement of cash flows
8
Notes to the condensed half-year consolidated financial statements as of June 30, 2026
10
Introduction
10
A/ Basis of preparation of the half-year financial statements and accounting policies
10
B/ Significant information for the first half of 2026
13
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
1
Exhibit 99.1
-
Condensed half-year consolidated financial statements
-
Condensed half-year consolidated
financial statements
Consolidated balance sheets - assets
(Unaudited(1))
(€ million)
Note
June 30, 2026
December 31, 2025
Property, plant and equipment owned
B.2.
10,364
10,052
Right-of-use assets
1,590
1,459
B.3.
41,954
41,300
Other intangible assets
B.3.
26,359
26,261
Investments accounted for using the equity method
B.5.
3,207
3,259
Other non-current assets
B.6.
4,732
4,364
Goodwill
Non-current income tax assets
569
550
Deferred tax assets
8,763
8,608
Non-current assets
97,538
95,853
11,127
10,214
Inventories
Accounts receivable
B.7.
Other current assets
Current income tax assets
Cash and cash equivalents
Assets held for sale
B.9.
8,714
8,410
4,282
4,066
492
397
6,350
7,657
557
208
Current assets
31,522
30,952
Total assets
129,060
126,805
The accompanying notes on pages 10 to 33 are an integral part of the condensed half-year consolidated financial statements.
(1)
2
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
Consolidated balance sheets - equity and liabilities
(Unaudited(1))
June 30, 2026
December 31, 2025
Equity attributable to equity holders of Sanofi
(€ million)
Note
69,207
71,376
Equity attributable to non-controlling interests
360
334
Total equity
B.8.
69,567
71,710
Long-term debt
B.9.
14,646
14,248
1,677
1,467
Non-current lease liabilities
Non-current liabilities related to business combinations and to non-controlling interests
B.11.
652
585
Non-current provisions and other non-current liabilities
B.12.
6,848
6,703
2,187
2,081
Non-current income tax liabilities
Deferred tax liabilities
1,553
1,666
Non-current liabilities
27,563
26,750
7,150
7,361
Accounts payable
Current liabilities related to business combinations and to non-controlling interests
B.11.
Current provisions and other current liabilities
Current income tax liabilities
Current lease liabilities
Short-term debt and current portion of long-term debt
B.9.
Liabilities related to assets held for sale
Current liabilities
Total equity and liabilities
—
—
16,446
15,565
884
751
227
272
7,026
4,342
197
54
31,930
28,345
129,060
126,805
The accompanying notes on pages 10 to 33 are an integral part of the condensed half-year consolidated financial statements.
(1)
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
3
Exhibit 99.1
- Condensed half-year consolidated financial statements
Consolidated income statements
(Unaudited(1))
(€ million)
Note
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net sales
B.20.
22,106
19,889
Other revenues
B.20.
1,438
1,452
Cost of sales
(6,155)
(5,881)
Gross profit
17,389
15,460
Research and development expenses
(3,980)
(3,717)
Selling and general expenses
(4,792)
(4,506)
Other operating income
B.15.
800
533
Other operating expenses
B.15.
(3,436)
(2,476)
Amortization of intangible assets
B.3.
(1,087)
(777)
Impairment of intangible assets
B.4.
(1,031)
(210)
Fair value remeasurement of contingent consideration
B.6.
B.11.
(37)
(61)
Restructuring costs and similar items
B.16.
(563)
(430)
Other gains and losses, and litigation
B.17.
(95)
(57)
Operating income
3,168
3,759
Financial expenses
B.18.
(465)
(361)
Financial income
B.18.
137
184
2,840
3,582
(871)
(711)
Income before tax and investments accounted for using the equity method
Income tax expense
B.19.
Share of profit/(loss) from investments accounted for using the equity method
Net income from continuing operations
Net income from discontinued operations
B.22.
Net income
2
85
1,971
2,956
26
2,881
1,997
5,837
Net income attributable to non-controlling interests
40
25
Net income attributable to equity holders of Sanofi
1,957
5,812
2.40
•
Basic earnings per share from continuing operations (€)
1.61
•
Basic earnings per share from discontinued operations (€)
0.02
2.34
1.63
4.74
Basic earnings per share (€)
B.8.7.
•
Diluted earnings per share from continuing operations (€)
1.60
2.39
•
Diluted earnings per share from discontinued operations (€)
0.02
2.33
1.62
4.72
Diluted earnings per share (€)
B.8.7.
The accompanying notes on pages 10 to 33 are an integral part of the condensed half-year consolidated financial statements.
(1)
4
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
Consolidated statements of comprehensive income
(Unaudited(1))
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net income
1,997
5,837
Attributable to equity holders of Sanofi
1,957
5,812
Attributable to non-controlling interests
40
25
(€ million)
Note
Other comprehensive income:
•
Actuarial gains/(losses)
B.8.8.
158
111
•
Change in fair value of equity instruments included in financial assets and financial liabilities
B.8.8.
175
222
•
Tax effects
B.8.8.
Subtotal: items not subsequently reclassifiable to profit or loss from continuing operations (A)
(43)
(92)
290
241
•
Change in fair value of debt instruments included in financial assets
B.8.8.
5
3
•
Change in fair value of cash flow hedges
B.8.8.
14
(23)
•
Change in currency translation differences
B.8.8.
1,313
(5,203)
•
Tax effects
B.8.8.
(5)
(95)
Subtotal: items subsequently reclassifiable to profit or loss from continuing operations (B)
1,327
(5,318)
Other comprehensive income/(loss) from continuing operations for the period, net of taxes (A+B)
1,617
(5,077)
Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)
—
303
Comprehensive income
3,614
1,063
Attributable to equity holders of Sanofi
3,562
1,076
•
Continuing operations
3,536
(2,097)
•
Discontinued operations
26
3,173
52
(13)
Attributable to non-controlling interests
The accompanying notes on pages 10 to 33 are an integral part of the condensed half-year consolidated financial statements.
(1)
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
5
Exhibit 99.1
- Condensed half-year consolidated financial statements
Consolidated statements of changes in equity
(Unaudited(1))
Treasury
shares
Reserves
and
retained
earnings
Stock
options and
other
sharebased
payments
Other
comprehensive
income
Attributable to
equity
holders of
Sanofi
Attributable to noncontrolling
interests
Total
equity
(€ million)
Share
capital
Additional
paid-in
capital
Balance at January 1, 2025
2,526
—
(840)
68,185
5,260
2,376
77,507
350
77,857
Other comprehensive income for
the period
—
—
—
243
—
(4,979)
(4,736)
(38)
(4,774)
Net income for the period
—
—
—
5,812
—
—
5,812
25
5,837
Comprehensive income for the
period
—
—
—
6,055
—
(4,979)
1,076
(13)
1,063
Dividend paid out of 2024
earnings (€3.92 per share)
—
—
—
(4,772)
—
—
(4,772)
—
(4,772)
—
—
—
—
—
—
—
(32)
(32)
(3,988)
Payment of dividends to noncontrolling interests
—
—
(3,988)
—
—
—
(3,988)
—
Reduction in share capital
(74)
—
3,868
(3,794)
—
—
—
—
—
Tax on share cancellations (b)
—
—
(15)
—
—
—
(15)
—
(15)
Share repurchase program
(a)
Share-based payment plans:
•
Exercise of stock options
1
14
—
—
—
—
15
—
15
•
Issuance of restricted shares
and vesting of existing
restricted shares
3
(3)
—
—
—
—
—
—
—
•
Value of services obtained
from employees
—
—
—
—
177
—
177
—
177
•
Tax effects of share-based
payments
—
—
—
—
(7)
—
(7)
—
(7)
Other changes arising from
issuance of restricted shares (c)
—
—
—
15
—
—
15
—
15
Changes in non-controlling
interests (d)
—
—
—
—
—
—
—
(34)
(34)
Balance at June 30, 2025
2,456
11
(975)
65,689
5,430
(2,603)
70,008
271
70,279
Other comprehensive income for
the period
—
—
—
(71)
—
160
89
(5)
84
Net income for the period
—
—
—
2,001
—
—
2,001
13
2,014
Comprehensive income for
the period
—
—
—
1,930
—
160
2,090
8
2,098
Payment of dividends to noncontrolling interests
—
—
—
—
—
—
—
(12)
(12)
Share repurchase program (a)
—
—
(1,027)
—
—
—
(1,027)
—
(1,027)
Reduction in share capital
(22)
(170)
934
(742)
—
—
—
—
—
Tax on share cancellations (b)
—
—
(4)
—
—
—
(4)
—
(4)
Share-based payment plans:
•
Exercise of stock options
—
—
—
—
—
—
—
—
—
•
Issuance of restricted shares
and vesting of existing
restricted shares
—
—
—
—
—
—
—
—
—
•
Employee share ownership
plan
5
160
—
—
—
—
165
—
165
•
Value of services obtained
from employees
—
—
—
—
142
—
142
—
142
•
Tax effects of share-based
payments
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
68
68
2,439
1
(1,072)
66,877
5,572
(2,441)
71,376
334
71,710
Changes in non-controlling
interests (d)
Balance at December 31, 2025
(1)
6
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
(€ million)
Share
capital
Additional
paid-in
capital
Balance at January 1, 2026
Treasury
shares
Reserves
and
retained
earnings
Stock
options
and other
sharebased
payments
Other
comprehensive
income
Attributable to
equity
holders of
Sanofi
Attributable to noncontrolling
interests
Total
equity
2,439
1
(1,072)
66,877
5,572
(2,441)
71,376
334
71,710
Other comprehensive income for
the period
—
—
—
290
—
1,315
1,605
12
1,617
Net income for the period
—
—
—
1,957
—
—
1,957
40
1,997
Comprehensive income for
the period
—
—
—
2,247
—
1,315
3,562
52
3,614
Dividend paid out of 2025
earnings (€4.12 per share)
—
—
—
(4,923)
—
—
(4,923)
—
(4,923)
Payment of dividends to noncontrolling interests
—
—
—
—
—
—
—
(26)
(26)
Share repurchase program (a)
—
—
(1,003)
—
—
—
(1,003)
—
(1,003)
Reduction in share capital
(a)
(15)
—
596
(581)
—
—
—
—
—
Tax on share cancellations (b)
—
—
(3)
—
—
—
(3)
—
(3)
Share-based payment plans:
•
Exercise of stock options
—
3
—
—
—
—
3
—
3
•
Issuance of restricted shares
and vesting of existing
restricted shares (a)
4
(4)
102
(102)
—
—
—
—
—
•
Value of services obtained
from employees
—
—
—
—
184
—
184
—
184
•
Tax effects of share-based
payments
—
—
—
—
1
—
1
—
1
Other changes arising from
issuance of restricted shares (c)
—
—
—
10
—
—
10
—
10
2,428
—
(1,380)
63,528
5,757
(1,126)
69,207
360
69,567
Balance at June 30, 2026
(a) See Note B.8.2 and B.8.3. (for amounts relating to 2025, see Note D.15.4. to the consolidated financial statements for the year ended December 31,
2025).
(b) Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.
(c) This line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of
Opella.
(d) This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.
The accompanying notes on pages 10 to 33 are an integral part of the condensed half-year consolidated financial statements.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
7
Exhibit 99.1
- Condensed half-year consolidated financial statements
Consolidated statement of cash flows
(Unaudited(1))
(€ million)
Note
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net income attributable to equity holders of Sanofi
1,957
5,812
Net (income)/loss from the discontinued Opella business
(26)
(2,881)
Non-controlling interests
40
25
Share of undistributed earnings from investments accounted for using the equity method
94
(15)
2,880
1,779
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets
and intangible assets
Gains and losses on disposals of non-current assets, net of tax
(9)
(266)
Net change in deferred taxes
(218)
(539)
Net change in non-current provisions and other non-current liabilities (b)
195
(212)
Cost of employee benefits (stock options and other share-based payments)
184
171
Impact of the workdown of acquired inventories remeasured at fair value
210
—
Other profit or loss items with no cash effect on cash flows generated
by operating activities (c)
(74)
106
Operating cash flow before changes in working capital
5,233
3,980
(Increase)/decrease in inventories
(958)
(635)
(Increase)/decrease in accounts receivable
(27)
(785)
Increase/(decrease) in accounts payable
(340)
187
Net change in other current assets and other current liabilities
735
620
Net cash provided by/(used in) continuing operating activities
4,643
3,367
(a)
—
188
4,643
3,555
B.2. - B.3.
(1,296)
(1,420)
B.1.
(1,408)
(538)
Net cash provided by/(used in) operating activities of the discontinued Opella business
Net cash provided by/(used in) operating activities (d)
Acquisitions of property, plant and equipment and intangible assets
Acquisitions of consolidated undertakings and investments accounted for using the equity
method (e)
Acquisitions of other equity investments
(189)
(423)
Proceeds from disposals of property, plant and equipment, intangible assets and other noncurrent assets, net of tax (f)
424
434
Disposals of consolidated undertakings and investments accounted for using the equity method,
net of tax
78
—
Net change in other non-current assets
Net cash provided by/(used in) continuing investing activities
Net cash provided by/(used in) investing activities of the discontinued Opella business
Net cash inflow/(outflow) from the Opella transaction (g)
Net cash provided by/(used in) investing activities
Issuance of Sanofi shares
B.8.1.
(32)
(32)
(2,423)
(1,979)
—
(36)
(220)
10,742
(2,643)
8,727
18
29
(4,772)
Dividends paid:
•
to equity holders of Sanofi
(4,923)
•
to non-controlling interests
(25)
(27)
Additional long-term debt contracted
B.9.1.
2,304
2,993
Repayments of long-term debt
B.9.1.
(1,505)
(1,859)
Repayment of lease liabilities
(147)
(124)
Net change in short-term debt and other financial instruments (h)
1,955
3,322
(1,009)
(4,003)
(3,332)
(4,441)
Acquisitions of treasury shares and related tax effect
B.8.2
Net cash provided by/(used in) continuing financing activities
Net cash provided by/(used in) financing activities of the discontinued Opella business
Net cash provided by/(used in) financing activities
—
(48)
(3,332)
(4,489)
Impact of exchange rates on cash and cash equivalents
19
(42)
Cash and cash equivalents reclassified to Assets held for sale as of December 31, 2024
—
167
(1,313)
7,918
Net change in cash and cash equivalents
Cash and cash equivalents, beginning of period
(i)
Cash and cash equivalents, end of period
(1)
8
B.9.
7,663
7,441
6,350
15,359
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
(a) Includes non-current financial assets and deferred taxes, amounting to zero as of June 30, 2026 and to €48 million as of June 30, 2025.
(b) This line item includes contributions paid to pension funds (see Note B.12.).
(c) This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional
currencies and on instruments used to hedge such items.
(d) Of which:
June 30, 2026
(6 months)
June 30, 2025
(6 months)
•
Income tax paid
(925)
(1,355)
•
Interest paid
(260)
(206)
•
Interest received
111
170
•
Dividends received from non-consolidated entities
3
5
(e) This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the
six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months
ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.
(f) For the six months ended June 30, 2026 and June 30, 2025, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to
portfolio rationalization, and (ii) equity and debt instruments.
(g) For the six months ended June 30, 2025, this amount includes €(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.
(h) For the six months ended June 30, 2026, this line item mainly comprises (i) a commercial paper program in the United States for €2,388 million and (ii) a
cash outflow of €249 million arising from the settlement of the financial liabilities of Dynavax, acquired on February 10, 2026 (see Note B.1.1.). For the six
months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for €3,353 million.
(i) Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
9
Exhibit 99.1
- Condensed half-year consolidated financial statements
Notes to the condensed half-year consolidated financial
statements as of June 30, 2026
(Unaudited(1))
Introduction
Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged
in the research, development and marketing of therapeutic solutions focused on patient needs.
Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY).
The condensed consolidated financial statements for the six months ended June 30, 2026 were reviewed by the Sanofi Board of
Directors at the Board meeting on July 29, 2026.
A/ Basis of preparation of the half-year financial statements and accounting policies
A.1. International financial reporting standards (IFRS)
The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with
IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the
period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025.
The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2026 comply with
international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International
Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following
web link: https://www.efrag.org/en/financial-reporting/endorsement-status.
The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial
statements for the year ended December 31, 2025.
On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial
instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.
On July 18, 2024, the IASB issued Volume 11 of “Annual Improvements to IFRS”, applicable from January 1, 2026. Those
improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the
financial statements.
On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and
IFRS 7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided
in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of
December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi’s Form 20-F for the
year ended December 31, 2025 (the “2025 20-F”).
In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two
top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the
2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).
A.2. Use of estimates and judgments
The preparation of financial statements requires management to make reasonable estimates and assumptions based on
information available at the date the financial statements are finalized. Those estimates and assumptions may affect the
reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets
and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:
•
•
•
•
amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;
impairment of property, plant and equipment and intangible assets;
the valuation of goodwill and the valuation and useful life of acquired intangible assets; and
the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and
environmental risks.
Actual results could differ from these estimates.
For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis
of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial
income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity
(1)
These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi’s audited fullyear consolidated financial statements as of December 31, 2025.
10
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax
rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.
A.3. Seasonal trends
Sanofi’s activities are not subject to significant seasonal fluctuations.
A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in
hyperinflationary economies
In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that
the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the
Venezuelan subsidiaries to the consolidated financial statements is immaterial.
In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices
used to measure inflation in that country. Consequently, Sanofi has (since July 1, 2018) treated Argentina as a hyperinflationary
economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.
In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used
to measure inflation in that country. Consequently, Sanofi has (since January 1, 2022) treated Turkey as a hyperinflationary
economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.
A.5. Fair value of financial instruments
Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be
classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:
• Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);
• Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are
derived from observable market data; and
• Level 3: valuation techniques in which not all important inputs are derived from observable market data.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
11
Exhibit 99.1
- Condensed half-year consolidated financial statements
The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial
instruments.
Method used to determine fair value
Type of financial
Note instrument
Level in
Measurement fair value
principle
hierarchy
Market data
Valuation
technique
Valuation
model
Exchange
rate
Interest rate
Volatilities
B.6.
Financial assets
measured at fair value
(quoted equity
instruments)
Fair value
1
Market value
Quoted
market price
N/A
B.6.
Financial assets
measured at fair value
(quoted debt
instruments)
Fair value
1
Market value
Quoted
market price
N/A
B.6.
Financial assets
measured at fair value
(unquoted equity
instruments)
Fair value
3
Amortized
cost/ Peer
comparison
(primarily)
If cost ceases to be a representative measure of fair value, an internal
valuation based primarily on peer comparison is used.
B.6.
Financial assets
measured at fair value
(contingent
consideration receivable)
Fair value
3
Revenuebased
approach
The fair value of contingent consideration receivable is determined by
adjusting the contingent consideration at the end of the reporting period
using the method described in Note D.7.3. to the consolidated financial
statements for the year ended December 31, 2025.
B.6.
Long-term loans and
advances and other noncurrent receivables
Amortized
cost
N/A
N/A
B.6.
Financial assets
measured at fair value
held to meet obligations
under post-employment
benefit plans
Fair value
1
Market value
Quoted
market price
N/A
B.6.
Financial assets
designated at fair value
held to meet obligations
under deferred
compensation plans
Fair value
1
Market value
Quoted
market price
N/A
B.9.
Investments in mutual
funds
Fair value
1
Market value
Net asset
value
N/A
B.9.
Negotiable debt
instruments, commercial
paper, instant access
deposits and term
deposits
Amortized
cost
N/A
N/A
Because these instruments have a maturity of less than 3 months,
amortized cost is regarded as an acceptable approximation of fair value as
disclosed in the notes to the consolidated financial statements.
The amortized cost of long-term loans and advances and other noncurrent receivables at the end of the reporting period is not materially
different from their fair value.
B.9.
B.12.
Financial liabilities
Amortized
cost (a)
N/A
N/A
In the case of financial liabilities with a maturity of less than 3 months,
amortized cost is regarded as an acceptable approximation of fair value as
reported in the notes to the consolidated financial statements.
For financial liabilities with a maturity of more than 3 months, fair value as
reported in the notes to the consolidated financial statements is
determined either by reference to quoted market prices at the end of the
reporting period (quoted instruments) or by discounting the future cash
flows based on observable market data at the end of the reporting period
(unquoted instruments).
For financial liabilities based on variable payments such as royalties, fair
value is determined on the basis of discounted cash flow projections.
B.9.
Lease liabilities
Amortized
cost
N/A
N/A
Future lease payments are discounted using the incremental borrowing
rate.
B.10.
Forward currency
contracts
Fair value
2
Revenuebased
approach
Present value
of future
cash flows
Mid Market
Spot
< 1 year: Mid Money Market
1 year: Mid Zero Coupon
N/A
B.10.
Interest rate swaps
Fair value
2
Revenuebased
approach
Present value
of future
cash flows
Mid Market
Spot
< 1 year: Mid Money Market and
Euronext interest rate futures
1 year: Mid Zero Coupon
N/A
B.10.
Cross-currency swaps
Fair value
2
Revenuebased
approach
Present value
of future
cash flows
Mid Market
Spot
< 1 year: Mid Money Market and
Euronext interest rate futures
1 year: Mid Zero Coupon
N/A
B.11.
Liabilities related to
business combinations
and to non-controlling
interests
Fair value
3
Revenuebased
approach
Under IAS 32, contingent consideration payable in a business combination
is a financial liability. The fair value of such liabilities is determined by
adjusting the contingent consideration at the end of the reporting period
using the method described in Note B.11.
(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes
changes in fair value attributable to the hedged risk(s).
12
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
A.6. New pronouncements issued by the IASB and applicable from 2027
On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027.
In terms of adapting Sanofi’s chart of accounts and financial information systems, the transition is continuing on schedule. In line
with the information communicated in the 2025 financial statements as published, Sanofi’s IFRS 18 rollout project – which began
in the fourth quarter of 2025 – is progressing, and the impact analysis has evolved in line with the schedule. The future structure
of Sanofi’s consolidated income statement will present operating expenses by function, and will reflect presentational choices
based on the “useful structured summary” principle established by IFRS 18. Those choices involve the classification of income
statement items according to five categories (operating, investing, financing, income tax and discontinued operations), with the
sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a
whole operates a single principal activity. As regards the requirement to disclose alternative management performance
measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant
MPMs. In accordance with the information communicated in Sanofi’s 2025 consolidated financial statements, the main MPMs are
“Business gross profit”, “Business operating income” and “Business net income”, all of which are non-IFRS measures that Sanofi
currently uses in its financial communication. No significant impact on these performance measures has been identified at this
stage.
The transition note intended for publication in Sanofi’s 2026 Annual Report on Form 20-F will include a reconciliation, for the
comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with
IFRS 18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).
Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from Operating
income instead of Net income attributable to equity holders of Sanofi.
Finally, as mentioned in Sanofi’s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.
On November 13, 2025, the IASB issued “Translation to a Hyperinflationary Presentation Currency”, an amendment to IAS 21 (The
Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European
Union). Sanofi does not expect any material impact and will not early adopt this amendment.
B/ Significant information for the first half of 2026
B.1. Significant transactions for the first half of 2026
B.1.1. Acquisition of Dynavax Technologies Corporation
On February 10, 2026, Sanofi finalized the acquisition of Dynavax Technologies Corporation (Dynavax), a vaccines company with
a marketed adult hepatitis B vaccine (HEPLISAV-B) and a differentiated shingles vaccine candidate. The acquisition augments
Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi’s global scale, development
capabilities and commercial reach.
Dynavax’s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the United States and is differentiated by its two-dose
regimen over one month, enabling high levels of seroprotection faster than other hepatitis B vaccines (which are given in three
doses over six months).
The acquisition also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 clinical development,
and additional vaccine pipeline projects.
The transaction involved a cash tender offer by Sanofi to acquire all outstanding shares of Dynavax for $15.50 per share in cash,
reflecting a total equity value on a fully diluted basis of approximately $2.2 billion, including the subsequent reimbursement of
the short-term debt for $0.3 billion.
The provisional purchase price allocation led to the recognition of €204 million of goodwill, determined as follows:
(€ million)
Fair value at acquisition date
Other intangible assets
1,150
Other current and non-current assets and liabilities
429
Cash and cash equivalents
169
Short-term debt
(249)
Deferred taxes, net
(132)
Net assets of Dynavax
1,367
Goodwill
204
Purchase price
1,571
“Other intangible assets” mainly comprise Dynavax’s marketed vaccine HEPLISAV-B.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
13
Exhibit 99.1
- Condensed half-year consolidated financial statements
Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of
Dynavax into the Sanofi group.
The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.
Dynavax's contributions to Biopharma segment net sales and business operating income (for a definition refer to Note B.21.
“Segment Information”) since the acquisition date amount to €144 million and €89 million, respectively. Over the same period,
Dynavax made a negative contribution of €63 million to consolidated net income, including amortization of intangible assets of
€38 million; amortization and expenses arising from the impact of acquired inventories of €44 million; and restructuring costs
and similar items of €63 million.
The impact of this acquisition, as reflected within the line item Acquisitions of consolidated undertakings and investments
accounted for using the equity method in the consolidated statement of cash flows, is a net cash outflow of €1,403 million.
B.1.2. Proposed divestment of Medley, Sanofi’s Brazilian generics business
On March 6, 2026, Sanofi and EMS Group, a major pharmaceutical conglomerate in Brazil, announced the signing of a definitive
agreement for the purchase and sale of 100% of Medley, one of Brazil’s leading generic drug brands.
With effect from that date, given that completion of the transaction is considered highly probable, all of the assets of Medley,
and the liabilities directly associated with those assets (subsequently transferred to Medley Farmaceutica Ltda, a new legal entity
formed on May 1, 2026, the equity interests in which will be divested), are presented in the consolidated balance sheet within the
line items Assets held for sale and Liabilities related to assets held for sale, in accordance with IFRS 5 (Non-Current Assets
Held for Sale and Discontinued Operations); they are the main component of those line items as of June 30, 2026.
Sanofi’s Brazilian generics business does not meet the definition of a discontinued operation under IFRS 5 (see Note B.7. to the
consolidated financial statements for the year ended December 31, 2025), as a result of which the net income from this business
is not presented separately in the income statement.
A net gain is expected upon closing of the transaction. Consequently, no impairment was recognized on the carrying amount of
the net assets of Medley Farmaceutica Ltda as of the date of reclassification as held for sale.
The transaction is expected to close no earlier than the fourth quarter of 2026 subject to the fulfilment of customary closing
conditions, primarily clearance from the Brazilian Antitrust Authority (Administrative Council for Economic Defense – CADE).
B.2. Property, plant and equipment
The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:
June 30, 2026 June 30, 2025
(€ million)
Acquisitions
763
702
Biopharma
763
663
594
453
Opella (discontinued operation)
—
39
Of which capitalized interest
23
22
Of which Manufacturing & Supply
Firm orders for property, plant and equipment stood at €1,336 million as of June 30, 2026.
B.3. Goodwill and other intangible assets
Goodwill amounted to €41,954 million as of June 30, 2026, versus €41,300 million as of December 31, 2025. The movement
during the period reflects the impact of changes in exchange rates and the recognition of the goodwill arising on the Dynavax
acquisition (see note B.1.1.), partially offset by the reclassification of the goodwill relating to the Brazilian generics business to
Assets held for sale as a result of the proposed divestment (see note B.1.2.).
Movements in other intangible assets during the first half of 2026 were as follows:
14
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
(€ million)
Acquired R&D
Products,
trademarks and
other rights
Software
Total other
intangible assets
14,951
66,746
1,888
83,585
Changes in scope of consolidation (a)
—
1,149
1
1,150
Acquisitions and other increases
321
122
88
531
Disposals and other decreases
(534)
(17)
(28)
(579)
Currency translation differences
324
1,232
12
1,568
Transfers (b)
(245)
(162)
(4)
(411)
Gross value at January 1, 2026
Gross value at June 30, 2026
14,817
69,070
1,957
85,844
Accumulated amortization and impairment at January 1, 2026
(6,220)
(49,624)
(1,480)
(57,324)
—
(1,106)
(58)
(1,164)
Impairment losses, net of reversals (c)
Amortization expense
(970)
(61)
(17)
(1,048)
Disposals and other decreases
534
17
26
577
Currency translation differences
(135)
(785)
(10)
(930)
—
400
4
404
(6,791)
(51,159)
(1,535)
(59,485)
Carrying amount at January 1, 2026
8,731
17,122
408
26,261
Carrying amount at June 30, 2026
8,026
17,911
422
26,359
Transfers (b)
Accumulated amortization and impairment at June 30, 2026
(a) The “Changes in scope of consolidation” line mainly comprises the intangible assets recognized as part of the Dynavax acquisition (see Note B.1.)
(b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets to Assets
held for sale.
(c) See Note B.4.
“Products, trademarks and other products” mainly comprise:
• marketed products, with a carrying amount of €17.1 billion as of June 30, 2026 (versus €16.2 billion as of December 31, 2025)
and a weighted average amortization period of approximately 11 years; and
• technological platforms brought into service, with a carrying amount of €0.8 billion as of June 30, 2026 (versus €0.9 billion as
of December 31, 2025) and a weighted average amortization period of approximately 18 years.
B.4. Impairment of intangible assets
The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment
losses of €1,031 million in the first half of 2026, mainly comprising a €952 million impairment loss taken against the amlitelimab
asset, corresponding to the entire carrying amount of this intangible asset.
B.5. Investments accounted for using the equity method
Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated
financial statements for the year ended December 31, 2025), and comprise:
(€ million)
% interest
June 30, 2026
December 31, 2025
48.2
2,965
2,934
EUROAPI (b)
29.6
38
64
Infraserv GmbH & Co. Höchst KG (c)
31.2
93
112
MSP Vaccine Company (d)
50.0
52
59
—
59
90
3,207
3,259
OPAL JV Co
(a)
Other investments
Total
(a) Following the loss of control of Opella in 2025, Sanofi holds 48.2% of OPAL JV Co (CD&R holds 50% and Bpifrance holds 1.8%). As of December 31, 2025
the investment included a €241 million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella
completion accounts as of April 30, 2025, this loan was converted into ordinary shares.
(b) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€1.33 as of June 30, 2026, and €2.27 as
of December 31, 2025).
(c) Joint venture.
(d) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.
Share of profit/(loss) from investments accounted for using the equity method showed net income of €2 million for the first
half of 2026 (including a net loss of €39 million for Sanofi’s share of losses from the associate OPAL JV Co), versus net income of
€85 million for the first half of 2025 (including net income of €11 million for Sanofi’s share of profits from the associate OPAL JV
Co for the period from May 1, 2025 through June 30, 2025).
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
15
Exhibit 99.1
- Condensed half-year consolidated financial statements
The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are
classified as related parties. The principal transactions and balances with related parties are summarized below:
(€ million)
June 30, 2026
June 30, 2025
31
29
Sales (c)
Royalties and other income
142
63
548
371
(c)
Purchases of goods and services (including research expenses) (c)
June 30, 2026 December 31, 2025
(€ million)
Accounts receivable and other receivables (a)
430
Other assets (b)
84
143
Other liabilities
379
710
588
(a) Includes loans to joint ventures and associates.
(b) In October 2024, Sanofi raised its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bond. The fair value of this
investment as of June 30, 2026 was €84 million, versus €143 million as of December 31, 2025.
(c) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through
June 30, 2025.
Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in
accordance with Sanofi’s consolidation timelines, are presented below:
(€ million)
June 30, 2026
June 30, 2025
2,657
887
(61)
24
Consolidated income statement
Net sales and other revenues (a)
Net income
(a)
Consolidated statement of comprehensive income
Other comprehensive income
83
(1)
Comprehensive income
22
23
(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.
(€ million)
June 30, 2026
December 31, 2025
Consolidated balance sheet
Non-current assets
16,673
15,013
Current assets
2,925
2,859
Total assets
19,598
17,872
Equity attributable to equity holders of OPAL JV Co
5,958
5,380
Equity attributable to non-controlling interests
436
490
Total equity
6,394
5,870
Non-current liabilities
11,575
9,850
Current liabilities
1,629
2,152
Total liabilities
13,204
12,002
Total equity and liabilities
19,598
17,872
June 30, 2026
December 31, 2025
2,435
2,200
B.6. Other non-current assets
Other non-current assets comprise:
(€ million)
Equity instruments at fair value through other comprehensive income
Debt instruments at fair value through other comprehensive income
363
389
Other financial assets at fair value through profit or loss
1,099
1,004
194
Pre-funded pension obligations
203
Long-term prepaid expenses
185
175
Long-term loans and advances and other non-current receivables
421
393
Derivative financial instruments
26
9
4,732
4,364
Total
16
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.7. Accounts receivable
Accounts receivable break down as follows:
June 30, 2026
December 31, 2025
Gross value
8,818
8,510
Allowances
(104)
(100)
Carrying amount
8,714
8,410
(€ million)
The impact of allowances against accounts receivable in the first half of 2026 was a net expense of €6 million (versus a net
expense of €4 million for the first half of 2025).
The table below shows the ageing profile of overdue accounts receivable, based on gross value:
Overdue accounts
gross value
Overdue by
<1 month
Overdue by
1-3 months
Overdue by
3-6 months
Overdue by
6-12 months
Overdue by
12 months
June 30, 2026
522
183
127
142
27
43
December 31, 2025
468
184
134
71
27
52
(€ million)
Amounts overdue by more than one month relate mainly to public-sector customers.
Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of
receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended
December 31, 2025 and hence were derecognized was €11 million as of June 30, 2026 (versus zero as of December 31, 2025). The
residual guarantees relating to those transfers were immaterial as of June 30, 2026.
B.8. Consolidated shareholders’ equity
B.8.1. Share capital
As of June 30, 2026, the share capital was €2,428,198,054 and consisted of 1,214,099,027 shares (the total number of shares
outstanding) with a par value of €2.
Treasury shares held by Sanofi are as follows:
Number of shares
(million)
% of share capital
for the period
June 30, 2026
16.03
1.320%
December 31, 2025
11.96
0.981%
June 30, 2025
10.66
0.868%
January 1, 2025
9.53
0.755%
A total of 30,070 shares were issued in the first half of 2026 as a result of the exercise of Sanofi stock subscription options.
In addition, 3,072,520 shares vested under Sanofi restricted share plans during the first half of 2026, of which 1,886,523 were
fulfilled by issuance of new shares and 1,185,997 by allotment of existing shares free of charge.
B.8.2. Repurchase of Sanofi shares
On April 30, 2025, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18
months. Under that program, Sanofi repurchased 12,571,455 of its own shares during the first half of 2026 for a total amount of
€1,003 million.
During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's
shares, for an amount not exceeding €5 billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its
19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder
L'Oréal on February 2, 2025 for the acquisition of 2.34% of Sanofi’s share capital, equivalent to 29,556,650 shares, for a total
amount of approximately €3 billion, representing a price of €101.50 per share. The conclusion of that agreement was approved
by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth
in Articles L. 225-38 et seq. of the French Commercial Code.
On April 29, 2026, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18
months. Sanofi did not use that authorization during the first half of 2026.
B.8.3. Reduction in share capital
During the first half of 2026, treasury shares amounting to €596 million were cancelled further to decisions taken by the Sanofi
Board of Directors on March 4, 2026.
Those reductions have no impact on shareholders’ equity, except for the impact of the tax on share cancellations.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
17
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.8.4. Restricted share plans
Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial
statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:
2026
Type of plan
Performance share plan
Date of Board meeting approving the plan
April, 29, 2026
Date of Board meeting approving the plans awarded to the Chief Executive Officer
May 1, 2026
Total number of shares subject to a 3-year service period
5,087,518
Of which with no market condition
3,367,862
Fair value per share awarded (a)
€65.86
Of which with market conditions
1,719,656
Fair value per share awarded other than to the Chief Executive Officer (1,674,656 shares in total) (b)
Fair value per share awarded to the Chief Executive Officer (45,000 shares)
€57.99
€53.46
(b)
Total number of shares subject to a 5-year service period
180,000
Fair value per share awarded to the Chief Executive Officer (180,000 shares) (c)
€40.46
Fair value of plans at the date of grant (€ million)
329
(a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.
(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for
dividends expected during the vesting period of 3 years.
(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for
dividends expected during the vesting period of 5 years.
The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in
the table below:
June 30, 2026
Total expense for restricted share plans (€ million)
Number of shares not yet fully vested
June 30, 2025
138
146
12,995,668
11,550,347
Under 2026 plans
5,267,518
—
Under 2025 plans
3,897,342
4,020,451
Under 2024 plans
3,772,461
4,110,089
Under 2023 plans
58,347
3,313,588
Under 2022 plans
—
106,219
B.8.5. Employee stock purchase plans
On January 28, 2026, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the
opportunity to subscribe for new Sanofi shares at a price of €59.87 per share. The subscription period was open from June 9
through June 29, 2026. Sanofi employees subscribed for a total of 2,431,494 shares, and the resulting capital increase was
supplemented by the immediate issuance of a further 104,327 shares for the employer’s contribution. The total expense
recognized for this plan in the first half of 2026 was €46 million, determined in accordance with IFRS 2 (Share-Based Payment)
on the basis of the discount granted to the employees.
On January 29, 2025, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the
opportunity to subscribe for new Sanofi shares at a price of €72.97 per share. The subscription period was open from June 10
through June 30, 2025. Sanofi employees subscribed for a total of 2,260,776 shares, and the resulting capital increase was
supplemented by the immediate issuance of a further 116,794 shares for the employer’s contribution. The total expense
recognized for this plan in the first half of 2025 was €31 million, determined in accordance with IFRS 2 (Share-Based Payment) on
the basis of the discount granted to the employees.
B.8.6. Stock subscription option plans
No stock subscription option plans were awarded in the first half of 2026 or in 2025.
No further stock option plan expenses were recognized through equity in either the first half of 2026 or 2025.
18
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
The table below provides summary information about options outstanding and exercisable as of June 30, 2026:
Outstanding
Exercisable
Number of options
Weighted average
residual life
(years)
Number of options
Weighted average
exercise price
per share
(€)
From €60.00 to €70.00 per share
168,784
1.84
65.84
168,784
65.84
From €70.00 to €80.00 per share
213,400
2.84
76.71
213,400
76.71
From €80.00 to €90.00 per share
257,010
0.86
88.97
257,010
88.97
Total
639,194
Range of exercise prices per share
Weighted average
exercise price
per share
(€)
639,194
B.8.7. Earnings per share
Net income:
(€ million)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net income attributable to equity holders of Sanofi
1,957.0
5,812.0
of which net income from continuing operations
1,931.0
2,941.0
of which net income from discontinued operations
26.0
2,871.0
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Number of shares:
(number of shares in million)
Average number of shares outstanding
1,200.4
1,225.5
Adjustment for stock options with dilutive effect
—
0.1
Adjustment for restricted shares
5.1
5.1
1,205.5
1,230.7
Average number of shares used to compute diluted earnings per share
As of June 30, 2026 and June 30, 2025, all stock options were taken into account in computing diluted earnings per share
because they all had a dilutive effect.
Earnings per share:
Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and
restricted shares.
(in euros)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
2.40
•
Basic earnings per share from continuing operations (€)
1.61
•
Basic earnings per share from discontinued operations (€)
0.02
2.34
Basic earnings per share (€)
1.63
4.74
•
Diluted earnings per share from continuing operations (€)
1.60
2.39
•
Diluted earnings per share from discontinued operations (€)
0.02
2.33
1.62
4.72
HALF-YEAR FINANCIAL REPORT 2026
19
Diluted earnings per share (€)
SANOFI
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.8.8. Other comprehensive income
Movements within other comprehensive income are shown below:
(€ million)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
157
105
Actuarial gains/(losses):
▪ Actuarial gains/(losses) excluding investments accounted for using the equity method
▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes
1
1
(20)
(25)
▪ Change in fair value (excluding investments accounted for using the equity method)
175
222
▪ Change in fair value (investments accounted for using the equity method, net of taxes)
—
—
▪ Equity risk hedging instruments designated as fair value hedges
—
—
▪ Tax effects
(23)
(60)
Items not subsequently reclassifiable to profit or loss
290
243
▪ Tax effects
Equity instruments included in financial assets and financial liabilities:
Debt instruments included in financial assets:
▪ Change in fair value (excluding investments accounted for using the equity method) (a)
5
3
▪ Change in fair value (investments accounted for using the equity method, net of taxes)
—
—
▪ Tax effects
—
—
▪ Change in fair value (excluding investments accounted for using the equity method) (b)
5
(23)
▪ Change in fair value (investments accounted for using the equity method, net of taxes)
9
—
▪ Tax effects
(2)
6
1,747
(5,266)
Cash flow hedges and fair value hedges:
Change in currency translation differences:
▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the
equity method) (c)
▪ Currency translation differences (investments accounted for using the equity method)
▪ Hedges of net investments in foreign operations
▪ Tax effects
Items subsequently reclassifiable to profit or loss
55
(26)
(489)
390
(3)
(101)
1,327
(5,017)
(a) Includes reclassifications to profit or loss: immaterial over all periods.
(b) Includes reclassifications to profit or loss: €1 million in the first half of 2026; €2 million in the first half of 2025.
(c) Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.
Includes reclassifications to profit or loss: a €146 million loss in the first half of 2026 and a €459 million loss in the first half of 2025 relating to the
deconsolidation of Opella.
B.9. Debt, cash and cash equivalents
Changes in financial position during the period were as follows:
June 30, 2026
December 31, 2025
Long-term debt
(€ million)
14,646
14,248
Short-term debt and current portion of long-term debt
7,026
4,342
Interest rate and currency derivatives used to manage debt
221
112
Total debt
21,893
18,702
Cash and cash equivalents
(6,350)
(7,657)
Interest rate and currency derivatives used to manage cash and cash equivalents
Net debt (a)
(30)
(37)
15,513
11,008
(a) Net debt does not include lease liabilities, which amounted to €1,904 million as of June 30, 2026 and €1,739 million as of December 31, 2025.
“Net debt” is a non-IFRS financial measure used by management and investors to measure Sanofi’s overall net indebtedness.
20
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.9.1. Net debt at value on redemption
A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown
below:
Value on redemption
Carrying amount at
June 30, 2026
(€ million)
Adjustment to debt
measured at fair
Amortized cost
value
June 30, 2026 December 31, 2025
Long-term debt
14,646
44
61
14,751
14,360
Short-term debt and current portion of
long-term debt
7,026
1
—
7,027
4,344
221
—
(131)
90
12
Total debt
21,893
45
(70)
21,868
18,716
Cash and cash equivalents
(6,350)
—
—
(6,350)
(7,657)
(30)
—
—
(30)
(37)
15,513
45
(70)
15,488
11,022
Interest rate and currency derivatives used
to manage debt
Interest rate and currency derivatives used
to manage cash and cash equivalents
Net debt (a)
(a) Net debt does not include lease liabilities, which amounted to €1,904 million as of June 30, 2026 and €1,739 million as of December 31, 2025.
The table below shows an analysis of net debt by type, at value on redemption:
December 31, 2025
June 30, 2026
(€ million)
Bond issues
non-current
current
Total
non-current
current
Total
18,301
14,306
3,165
17,471
3,340
54
936
990
14,702
3,599
Other bank borrowings
49
3,291
Other borrowings
—
1
1
—
1
1
Bank credit balances
—
136
136
—
242
242
Interest rate and currency derivatives used to
manage debt
—
90
90
—
12
12
(a)
Total debt
(b)
14,751
7,117
21,868
14,360
4,356
18,716
Cash and cash equivalents
—
(6,350)
(6,350)
—
(7,657)
(7,657)
Interest rate and currency derivatives used to
manage cash and cash equivalents
—
(30)
(30)
—
(37)
(37)
14,751
737
15,488
14,360
(3,338)
11,022
Net debt
(a) These amounts include $3 billion designated as a hedge of Sanofi’s net investment in the United States.
(b) As of June 30, 2026, current other bank borrowings include €3,217 million related to the US commercial paper program.
Principal financing and debt reduction transactions during the period
During the period, Sanofi carried out a bond issue of €2.3 billion in three tranches:
• €1,000 million of fixed-rate bonds maturing May 2029, with annual coupons and bearing interest at an annual rate of 3.000%;
• €650 million of fixed-rate bonds maturing May 2033, with annual coupons and bearing interest at an annual rate of 3.375%;
and
• €650 million of fixed-rate bonds maturing May 2037, with annual coupons and bearing interest at an annual rate of 3.750%.
One bond issue was redeemed during the period: a €1.5 billion issue from March 2018, redeemed at maturity on March 21, 2026.
As of June 30, 2026, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its
liquidity in connection with current operations:
• a syndicated credit facility of €4 billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further
extension options are available; and
• a syndicated credit facility of €3.85 billion, drawable in euros and US dollars and expiring on April 23, 2031, for which two
one-year extension options are available. This facility became effective on April 23, 2026, and replaced an existing €4 billion
facility that was cancelled on the same date and had originally been scheduled to mature on December 6, 2027.
As of June 30, 2026, neither facility was drawn down.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
21
Exhibit 99.1
- Condensed half-year consolidated financial statements
Sanofi also has two short-term debt programs:
• a €6 billion Negotiable European Commercial Paper program in France; and
• a $10 billion Commercial Paper program in the United States.
During the first half of 2026:
• the average drawdown under the US Commercial Paper program was $3.0 billion; and
• the average drawdown under the Negotiable European Commercial Paper program in France was €0.1 billion.
The financing in place as of June 30, 2026 at the level of the holding company (which manages most of Sanofi’s financing needs
centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.
B.9.2. Market value of net debt
The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:
(€ million)
June 30, 2026
December 31, 2025
Market value
14,989
10,424
Value on redemption
15,488
11,022
B.10. Derivative financial instruments
B.10.1 Currency derivatives used to manage operating risk exposures
The table below shows operating currency hedging instruments in place as of June 30, 2026. The notional amount is translated
into euros at the relevant closing exchange rate.
Of which derivatives not
eligible for hedge
accounting
Of which derivatives designated
as cash flow hedges
June 30, 2026
Notional
amount
Fair value
Notional
amount
Fair value
Of which
recognized
in equity
Notional
amount
Fair value
Forward currency sales
6,536
(66)
221
(8)
(8)
6,315
(58)
of which US dollar
(€ million)
2,968
(38)
—
—
—
2,968
(38)
of which Singapore dollar
555
—
—
—
—
555
—
of which Chinese yuan renminbi
530
(6)
—
—
—
530
(6)
of which Brazilian real (a)
422
(9)
221
(8)
(8)
201
(1)
of which Saudi Arabian riyal
224
(3)
—
—
—
224
(3)
Forward currency purchases
5,039
33
—
—
—
5,039
33
of which US dollar
3,200
24
—
—
—
3,200
24
of which Singapore dollar
596
2
—
—
—
596
2
of which Chinese yuan renminbi
306
2
—
—
—
306
2
of which Turkish lira
120
6
—
—
—
120
6
of which United Arab Emirates dirham
120
1
—
—
—
120
1
11,575
(33)
221
(8)
(8)
11,354
(25)
Total
(a) Includes forward sales with a notional amount of BRL 1,300 million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in
Brazil.
The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to
transactions carried out during the six months ended June 30, 2026 and recognized in the balance sheet at that date. Gains and
losses on hedging instruments (forward contracts) are calculated and recognized in parallel with the recognition of gains and
losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items
(hedging instruments and hedged transactions) will be immaterial in the second half of 2026.
B.10.2. Currency and interest rate derivatives used to manage financial exposure
The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi’s financing activities, expose
certain Sanofi entities to financial foreign exchange risk (i.e. the risk of changes in the value of loans and borrowings
denominated in a currency other than the functional currency of the lender or borrower).
That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the
currency split of Sanofi’s debt once those instruments are taken into account.
22
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
The table below shows financial currency hedging instruments in place as of June 30, 2026. The notional amount is translated
into euros at the relevant closing exchange rate.
June 30, 2026
(€ million)
Notional amount
1,523
Cross currency seller swaps
of which US dollar
1,523
Forward currency sales
16,423
of which US dollar
13,361
of which Pound sterling
1,401
of which Brazilian real
204
Forward currency purchases
Maximum
expiry date
Fair value
(37)
(37)
(a)
2032
(272)
(b)
(c)
11,466
(241)
2027
(7)
2026
(9)
2027
170
of which US dollar
8,657
143
2027
of which Singapore dollar
1,299
6
2026
of which Hungarian forint
543
19
2026
29,412
(139)
Total
(d)
(a) Comprises two cross currency swaps, (i) with a notional amount of $870 million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional
amount of $870 million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi’s net investment in the United States. As of June
30, 2026, the fair value of the swaps was a liability of €37 million, with €33 million debited to Other comprehensive income under the cost of hedging
accounting treatment and €4 million debited to financial result.
(b) Includes forward sales with a notional amount of $12,275 million expiring in 2026 and 2027, designated as a hedge of Sanofi’s net investment in the
United States. As of June 30, 2026, the fair value of these forward contracts represented a liability of €223 million, with €222 million debited to Other
comprehensive income and €1 million debited to Financial expenses.
(c) Includes forward sales with a notional amount of BRL 1,200 million expiring in 2027, designated as a hedge of Sanofi’s net investment in Brazil. As of
June 30, 2026, the fair value of these forward contracts represented a liability of €9 million, with €10 million debited to Other comprehensive income,
and €1 million credited to Financial income.
(d) Includes forward purchases with a notional amount of $1,000 million expiring in 2026, designated as a fair value hedge of the exposure of $1,000 million
of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of €6 million, with
€6 million debited to Financial expenses; the impact on Other comprehensive income is immaterial.
To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross
currency swaps) to alter the fixed/floating rate split of its net debt.
The table below shows instruments of this type in place as of June 30, 2026:
Of which
designated as fair
value hedges
Of which designated
as cash flow hedges
Of which
recognized
in equity
2026
2027
2028
2029
2030
and
beyond
pay 2.08% / receive Euribor 3M
—
850
—
—
—
850
(2)
—
—
850
(2)
(2)
pay 3.77% / receive
capitalized SOFR + 46bps
—
438
—
—
—
438
4
—
—
438
4
4
pay capitalized SOFR USD/
receive 1.03%
—
—
438
—
—
438
(25)
438
(25)
—
—
—
pay capitalized SOFR USD/
receive 1.32%
—
—
438
—
438
(22)
438
(22)
pay 3.82% / receive
capitalized SOFR USD + 54 bps
—
—
438
—
—
438
7
—
—
438
7
7
pay capitalized Ester/receive 0.92%
—
—
—
650
—
650
(28)
650
(28)
—
—
—
pay capitalized Ester / receive 2.53%
—
—
—
750
—
750
2
750
2
—
—
—
pay capitalized Ester / receive 2.71%
—
—
—
—
475
475
4
475
4
—
—
—
pay capitalized Ester / receive 2.91%
—
—
—
—
475
475
7
475
7
—
—
—
Total
—
1,288
1,313
1,400
950
4,951
(52)
3,226
(62)
1,726
10
10
(€ million)
Total
Fair
value
Notional
amount
Fair
value
Notional
Fair
amount value
Interest rate swaps
SANOFI
—
HALF-YEAR FINANCIAL REPORT 2026
23
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.11. Liabilities related to business combinations and to non-controlling interests
For a description of the nature of the liabilities reported in the line item Liabilities related to business combinations and to
non-controlling interests, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2025.
The liabilities related to business combinations and to non-controlling interests shown in the table below are level 3 instruments
under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).
Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown
below:
Shire
contingent
CVRs issued
CVRs issued
consideration in connection in connection
arising from
with the
with the
acquisition of acquisition of acquisition of
Translate Bio
Blueprint
Vigil
(€ million)
Other
Total (a)
Balance at January 1, 2026
531
48
5
1
585
Payments made
—
—
—
—
—
Fair value remeasurements through profit or loss: (gain)/loss (including
unwinding of discount) (b)
38
8
3
—
49
Currency translation differences
Balance at June 30, 2026
16
2
1
(1)
18
585
58
9
—
652
Of which:
•
Current portion
•
Non-current portion
—
652
(a) As of January 1, 2026, this comprised a non-current portion of €585 million.
(b) Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.
As of June 30, 2026, Liabilities related to business combinations and to non-controlling interests mainly comprised the
contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of
Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to
development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was
measured at €585 million as of June 30, 2026, compared with €531 million as of December 31, 2025. If the discount rate were to
fall by one percentage point, the fair value of the Shire liability would increase by approximately 13%.
B.12. Non-current provisions and other non-current liabilities
The line item Non-current provisions and other non-current liabilities comprises the following:
(€ million)
June 30, 2026
December 31, 2025
Provisions
4,592
Other non-current liabilities (a)
2,256
4,541
2,162
Total
6,848
6,703
(a) Includes €1,647 million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note
C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an
increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to
be due within more than one year but less than five years is €916 million; the nominal value of payments estimated to be due after more than five years
is €2,150 million.
The table below shows movements in provisions:
24
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
(€ million)
Provisions for
pensions & other
post-employment
benefits
Provisions for
other long-term
benefits
Restructuring
provisions
Other provisions
Total
1,440
827
654
1,620
4,541
13
13
Balance at January 1, 2026
Changes in scope of consolidation
—
—
—
57
(a)
Increases in provisions and other liabilities
Provisions utilized
110
180
126
473
(36)
(a)
(57)
(4)
(40)
(137)
Reversals of unutilized provisions
(13)
(a)
(2)
(60)
(54)
(129)
Transfers (b)
11
—
(104)
(20)
(113)
Net interest related to employee benefits, and
unwinding of discount
26
1
8
14
49
Currency translation differences
15
18
2
17
52
Actuarial gains and losses on defined-benefit
plans
(157)
—
—
—
(157)
Balance at June 30, 2026
1,343
897
676
1,676
4,592
(a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions and other liabilities” line corresponds to rights
vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to
beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments.
(b) Mainly transfers to Current provisions and other current liabilities.
Provisions for pensions and other post-employment benefits
For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2025, and
of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended
December 31, 2025.
The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone,
the United States and the United Kingdom were reviewed as of June 30, 2026 to take into account changes during the first half
of the year.
Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows
(amounts reported before tax):
June 30, 2025
(6 months)
June 30, 2026
(6 months)
(€ million)
Actuarial gains/(losses) on plan assets
71
Actuarial gains/(losses) on benefit obligations
86
(c)
(45)
(a)
152
(b)
(a) Includes the effects of (i) the change in discount rates (in a range between +0.05% and +0.50%) and (ii) the +0.15% change in the inflation rate in the
United Kingdom in the first half of 2026.
(b) Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the
United Kingdom in the first half of 2025.
(c) Includes actuarial gains/ (losses) related to Opella of €(4) million for the first half of 2025..
B.13. Off balance sheet commitments
Off balance sheet commitments to third parties as of December 31, 2025 are presented in Note D.21.1. to the consolidated
financial statements for the year ended December 31, 2025.
The principal commitments entered into the period are described below:
• In March 2026, Sanofi entered into an exclusive license agreement to develop, manufacture, and commercialize rovadicitinib
worldwide from CTTQ, a Sino Biopharmaceutical Limited subsidiary. Rovadicitinib is a global first-in-class oral small molecule
dual-target JAK/ ROCK inhibitor which received its first approval in China in February 2026 as a first-line treatment for MF
(myelofibrosis) indication. Under the terms of the agreement, CTTQ received an upfront payment of $135 million and is
entitled to receive up to $1.4 billion in development, regulatory and sales milestones, and up to double-digit tiered royalties on
product sales.
• In March 2026, Sanofi entered into a worldwide exclusive license agreement with Kali Therapeutics for a next-generation trispecific T-cell engager for autoimmune diseases, under which Sanofi will obtain exclusive worldwide rights to KT501, a novel
tri-specific antibody utilizing Kali Therapeutics’ proprietary discovery and research platform. Under the terms of the
agreement, Kali Therapeutics is entitled to receive up to $1.2 billion including upfront payments (of which $0.1 billion has
already been paid) plus development and sales milestones, and tiered royalties ranging from high-single to double digits on
product sales.
As of June 30, 2026, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of
its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in
the 2025 Form 20-F.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
25
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.14. Litigation and arbitration proceedings
Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related
to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent
protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge
claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements
relating to business divestitures.
The matters discussed below constitute the most significant developments since publication of the financial statements for the
year ended December 31, 2025.
B.14.1. Products
Zantac product litigation in the US
In the Multi-District Litigation (MDL) where Federal court cases were coordinated, the Eleventh Circuit held oral argument for
the appeal in the fourth quarter of 2025 and a decision is expected in the second half of 2026.
In those cases pending in Delaware (State court) where the issue is to rule on defendants’ Daubert motions to exclude plaintiffs’
experts, in the second quarter of 2026, the Delaware Superior Court granted summary judgment and dismissed all the cases
pending against Sanofi. The plaintiffs are appealing this ruling to the Delaware Supreme Court and Sanofi does not expect a
decision on the appeal until the fourth quarter of 2027.
It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.
Talc product litigation in the US
As of June 30, 2026, Sanofi was named as a defendant in approximately 1,430 ongoing product liability actions. To date, no
cases have proceeded to trial.
It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.
Dupixent product litigation in the US
Approximately 30 product liability cases have been filed in Federal courts around the country alleging that Dupixent (dupilumab)
causes or exacerbates T-Cell lymphoma. In June 2026, those cases were consolidated into a Multi-District Litigation (MDL) in
New Jersey Federal court. In addition, eight cases have been filed in New Jersey State court.
It is not possible, at this stage, to assess reliably the outcome of these ongoing cases.
B.14.2. Patents
Praluent (alirocumab)-related Amgen patent litigation in Europe
On March 6, 2026, Sanofi, Regeneron and Amgen entered into a settlement agreement resolving these disputes. The terms of
the settlement are confidential. These cases are now closed.
B.14.3. Other litigation
Plavix (clopidogrel) - Attorney General Action in Texas
In the action filed by Sanofi and Bristol Myers Squibb (BMS) against the Texas Attorney General (Texas AG) in Travis County, on
April 28, 2026 the Travis County court granted the Texas AG’s motion to abate the companies’ suit against it; and on June 4,
2026 the companies filed a mandamus petition with the Texas Court of Appeals seeking to vacate that ruling.
340B drug pricing program in the US
The US Health Resources and Services Administration (HRSA) withdrew its 340B Rebate Model Pilot Program in February 2026
but is expected to announce a new 340B Rebate Model Pilot Program later in 2026.
ADR Proceedings in the US
In the 340B Administrative Dispute Resolution (ADR) proceedings against Sanofi, one filed by University of Washington/
Harborview Medical Center in 2023 and one filed by Hudson Headwaters Health Network in 2024 (both alleging that Sanofi’s
340B Integrity Initiative caused “overcharges” under Section 340B), on March 9, 2026 the ADR Panel determined that there was
no overcharge violation by Sanofi in the proceeding involving University of Washington Medical Center/Harborview Medical
Center; and on May 27, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding
involving Hudson Headwaters Network, which has requested reconsideration of the ADR Panel’s decision.
Mosaic Health in the US
Since the case was remanded by the Court of Appeal to the District Court in August 2025 following the second amended
complaint filed by plaintiffs, defendants (Sanofi and three other manufacturers) filed a motion to dismiss certain state law claims.
Defendants also filed a petition for a writ of certiorari with the Supreme Court of the United States challenging two aspects of
the Second Circuit’s decision. In July 2026, certain state law claims and plaintiffs’ unjust enrichment claims were dismissed. The
District Court set a case schedule with fact discovery closing in November 2027.
26
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
Adventist Health System/West in the US
In the appeal filed by Adventist Health System/West following the dismissal granted by the court in March 2024 in favor of the
drug manufacturers including Sanofi, the Ninth Circuit Court of Appeals reversed and ordered the case to be remanded to the
District Court on March 17, 2026.
B.15. Other operating income and expenses
Other operating income amounted to €800 million in the first half of 2026 (versus €533 million in the first half of 2025), and
Other operating expenses to €3,436 million (versus € 2,476 million in the first half of 2025), as shown in the table below.
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net gains / (losses) on disposals of operating assets or businesses
241
344
Amvuttra licensing income
398
120
Other
161
69
800
533
(3,486)
(2,475)
(€ million)
Total other operating income
Regeneron alliance:
(i) (Profit)/loss sharing
(ii) Additional profit share for development cost from Regeneron
594
494
(iii) Selling expense reimbursements to Regeneron
(336)
(346)
Other
Total other operating expenses
(208)
(149)
(3,436)
(2,476)
June 30, 2026
(6 months)
B.16. Restructuring costs and similar items
Restructuring costs and similar items comprise the following:
Employee-related expenses
284
June 30, 2025
(6 months)
201
Charges, gains or losses on assets (a)
179
109
Costs of transformation programs
10
80
Other (b)
90
40
Total
563
430
(€ million)
(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or
losses on divestments of assets arising from reorganization decisions made by Sanofi.
(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to €73 million for the
first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).
B.17. Other gains and losses, and litigation
For the first half of 2026, Other gains and losses, and litigation represents a charge of €95 million mainly related to major
litigation, compared with a charge of €57 million in the first half of 2025.
B.18. Financial expenses and income
An analysis of financial expenses and income is set forth below:
June 30, 2026
(6 months)
(253)
June 30, 2025
(6 months)
(219)
Interest income (b)
118
162
Cost of net debt
(135)
(57)
(€ million)
Cost of debt (a)
Non-operating foreign exchange gains/(losses)
(3)
1
Unwinding of discounting of provisions (c)
(21)
(22)
Net interest cost related to employee benefits
(27)
(37)
Impairment losses on financial assets, net of reversals
Net interest expense on lease liabilities
(1)
—
(26)
(22)
Other (d)
(115)
(40)
Net financial income/(expenses)
(328)
(177)
comprising: Financial expenses
(465)
(361)
137
184
Financial income
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
27
Exhibit 99.1
- Condensed half-year consolidated financial statements
(a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €12 million in the first half of 2026 and €(25) million in the first
half of 2025.
(b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €6 million in the first half of 2026 and
€(4) million in the first half of 2025.
(c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).
(d) Includes a financial expense of €146 million for the six months ended June 30, 2026 and €50 million for the six months ended June 30, 2025 for the
remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.
The impact of the ineffective portion of hedging relationships was not material in either 2026 or 2025.
B.19. Income tax expense
Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the
United States.
The table below shows the allocation of income tax expense between current and deferred taxes:
(€ million)
Current taxes
June 30, 2026
(6 months)
June 30, 2025
(6 months)
(1,089)
(1,202)
Deferred taxes
218
491
Total
(871)
(711)
2,840
3,582
Income before tax and investments accounted for using the equity method
The difference between the effective tax rate (on income before tax and investments accounted for using the equity method)
and the standard corporate income tax rate applicable in France is explained as follows:
(as a percentage)
June 30, 2026
(6 months) (a)
June 30, 2025
(6 months)(a)
Standard tax rate applicable in France
25.8
25.8
Difference between the standard French tax rate and the rates applicable to Sanofi (b)
(17.9)
(7.3)
Tax effect related to amlitelimab
19.3
—
1.8
2.3
(c)
Revisions to tax exposures and settlements of tax disputes
Other (d)
Effective tax rate
1.5
(1.0)
30.6
19.8
(a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).
(b) This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patentfavorable tax regimes.
The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the
tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.
(c) This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax
assets.
(d) For the six months ended June 30, 2026, this line includes a tax expense of €57 million representing the estimated impact of Pillar Two based on
Sanofi’s current understanding of Pillar Two rules, compared with €17 million for the six months ended June 30, 2025.
28
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.20. Revenue from contracts with customers
B.20.1. Analysis of net sales
The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025
(€ million)
Europe
United
States
Other
countries
June 30,
2026
Europe
United
States
Other
countries
June 30,
2025
Total Group
4,304
11,633
6,169
22,106
4,144
9,535
6,210
19,889
1,146
6,922
1,256
9,324
944
5,283
1,085
7,312
ALTUVIIIO
—
576
98
674
—
456
86
542
525
Immunology
of which
Dupixent
Rare diseases
of which
Fabrazyme
138
256
129
523
134
261
130
Nexviazyme/Nexviadyme
152
211
63
426
132
195
60
387
Cerezyme
126
86
140
352
119
91
153
363
Ayvakit
44
322
1
367
—
—
—
—
Sarclisa
108
132
114
354
83
119
74
276
Lantus
146
344
323
813
149
395
332
876
Toujeo
259
134
336
729
248
126
318
692
Oncology
of which
Other medicines
of which
Plavix
40
2
398
440
44
3
426
473
Lovenox
202
5
157
364
247
9
191
447
Rezurock
36
218
42
296
23
220
20
263
181
7
2
190
241
1
9
251
Polio/pertussis/Hib primary
vaccines and boosters, incl.
Heplisav-B
206
487
671
1,364
223
320
818
1,361
RSV vaccines (Beyfortus)
87
65
240
392
85
68
203
356
Meningitis, travel and
endemics vaccines
118
268
179
565
96
319
194
609
Industrial sales
Vaccines
of which
COVID-19 and Influenza
vaccines
Of which total launches
33
16
72
121
52
54
108
214
546
1,891
610
3,047
423
1,204
473
2,100
B.20.2. Other revenues
June 30, 2026
(6 months)
June 30, 2025
(6 months)
VaxServe sales of non-Sanofi products
746
842
Sales to Opella (a)
60
61
Royalties
91
68
(€ million)
Other(b)
Total Biopharma Other revenues
Sales / Revenues from Opella products(c)
Total Other revenues
271
275
1,168
1,246
270
206
1,438
1,452
(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were
within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance
with IAS24 (see Note B.5.).
(b) This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.
(c) Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products
in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to
hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the
separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold
Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide
property rights).
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
29
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.21. Segment information
The segment information presented by Sanofi consists of a single operating segment: Biopharma.
The Biopharma operating segment comprises commercial operations and research, development and production activities
relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all
geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced
to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date,
corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier & Rice
(CD&R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing
operations, are presented within Other revenues in the income statement. The Biopharma operating segment also includes the
purchase price of Biopharma products manufactured by Opella.
The “Other” category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective
date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be
finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital
(Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with
the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution
agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained
subsidiary Gold Bond LLC (holder of the associated worldwide property rights).
B.21.1. Segment results
Sanofi reports segment results on the basis of “Business operating income”. This indicator is used internally by Sanofi’s chief operating
decision maker to measure the performance of the operating segment and to allocate resources.
“Business operating income” is derived from Operating income, adjusted as follows:
• amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or
operational nature) are eliminated;
• fair value remeasurements of contingent consideration relating to business combinations (IFRS 3) or business divestments,
and presented within the line item Fair value remeasurement of contingent consideration, are eliminated;
• expenses arising from the remeasurement of inventories following business combinations (IFRS 3) or acquisitions of groups of
assets that do not constitute a business within the meaning of paragraph 2b of IFRS 3, are eliminated;
• amounts reported within the line items Restructuring costs and similar items are eliminated;
• other gains and losses (including gains and losses on major divestments), presented within the line item Other gains and
losses, and litigation, are eliminated;
• other costs and provisions related to litigation, presented within the line item Other gains and losses, and litigation, are
eliminated;
• the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates
(i) to joint ventures or (ii) to associates with which Sanofi has entered into R&D agreements and/or whose operations are
managed as an integral part of Sanofi’s business activities, and;
• net income attributable to non-controlling interests related to continuing operations, and excluding the effects of the above
reconciling items, is deducted.
30
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
Segment results are shown in the table below:
June 30, 2026 (6 months)
(€ million)
Net sales
Biopharma
Other
June 30,
2026
Change vs.
June 30,
2025 on a
reported
basis (IFRS)
Change vs.
June 30,
2025 at
constant
exchange
rates (nonIFRS)
Total
June 30,
2026
Change vs.
June 30,
2025 on a
reported
basis (IFRS)
Change vs.
June 30,
2025 at
constant
exchange
rates (nonIFRS)
June 30,
2026
Change vs.
June 30,
2025 on a
reported
basis (IFRS)
Change vs.
June 30,
2025 at
constant
exchange
rates (nonIFRS)
+15.7%
22,106
+11.1%
+15.7%
22,106
+11.1%
Other revenues
1,168
-6.3%
-2.0%
270
+31.1%
+31.1%
1,438
-1.0%
+2.7%
Cost of sales
(5,812)
+1.0%
+3.8%
(133)
+3.9%
+3.1%
(5,945)
+1.1%
+3.8%
Research and development expenses
(3,979)
+7.1%
+9.9%
(1)
—%
—%
(3,980)
+7.1%
+9.9%
Selling and general expenses
(4,690)
+5.5%
+9.4%
(102)
+72.9%
+76.3%
(4,792)
+6.3%
+10.3%
+16.7%
+22.3%
(6)
(2,636)
Other operating income and expenses
(2,630)
Share of profit/(loss) from investments
accounted for using the equity method
74
74
Net income attributable to non-controlling
interests
(7)
(7)
Business operating income
As % of net sales
6,230
+16.5%
+22.2%
28
+75.0%
28.2%
+68.8%
6,258
28.3%
June 30, 2025 (6 months)
(€ million)
Biopharma
Net sales
19,889
Other
Total
19,889
Other revenues
1,246
206
1,452
Cost of sales
(5,753)
(128)
(5,881)
Research and development expenses
(3,716)
(1)
(3,717)
Selling and general expenses
(4,447)
(59)
(4,506)
Other operating income and expenses
(1,941)
(2)
(1,943)
Share of profit/(loss) from investments accounted for using the equity method
77
—
77
Net income attributable to non-controlling interests
(8)
—
(8)
5,347
16
5,363
Business operating income
The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income
before tax and investments accounted for using the equity method:
(€ million)
Business operating income
Share of profit/(loss) from investments accounted for using the equity method
(a)
Net income attributable to non-controlling interests(b)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
6,258
5,363
(74)
(77)
7
8
Amortization of intangible assets
(1,087)
(777)
Impairment of intangible assets(c)
(1,031)
(210)
Fair value remeasurement of contingent consideration
(37)
(61)
Expense arising from the impact of acquisitions on inventories(d)
(210)
—
Restructuring costs and similar items(e)
(563)
(430)
Other gains and losses, and litigation(f)
(95)
(57)
Operating income
3,168
3,759
Financial expenses
(465)
(361)
Financial income
137
184
2,840
3,582
Income before tax and investments accounted for using the equity method
(a) Mainly joint ventures.
(b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
(c) The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €1,031 million in the first half of 2026
mainly comprising a €952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly
comprises impairment losses of €210 million linked to research and development projects.
(d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026
relate to the Blueprint Medicines and Dynavax acquisitions.
(e) See Note B.16.
(f) See Note B.17.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
31
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.21.2. Other segment information
The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity
method related (a) to joint ventures or (b) to associates with which Sanofi has entered into R&D agreements and/or whose
operations are managed as an integral part of Sanofi’s business activities; (ii) acquisitions of property, plant and equipment; and
(iii) acquisitions of intangible assets.
Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH & Co.
Höchst KG (see Note B.5.).
Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.
Biopharma
(€ million)
June 30, 2026
June 30, 2025
Investments accounted for using the equity method
204
483
Acquisitions of property, plant and equipment
882
845
Acquisitions of other intangible assets
414
575
(a)
(a) Carrying amount at the end of the reporting period.
B.21.3. Information by geographical region
The geographical information on net sales provided below is based on the geographical location of the customer.
Net sales
(€ million)
June 30, 2026
June 30, 2025
4,304
4,144
Europe
of which France
725
835
United States
11,633
9,535
Rest of the World
6,169
6,210
of which China
1,325
1,388
22,106
19,889
Total
In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded
pension obligations, and right-of-use assets as determined under IFRS 16.
June 30, 2026
December 31, 2025
Property, plant
and equipment
Other
intangible
assets
Property, plant
and equipment
Other
intangible
assets
5,998
3,951
5,760
5,094
3,161
—
3,123
—
United States
2,270
21,972
2,229
20,694
Rest of the World
2,096
436
2,063
473
(€ million)
Europe
of which France
of which China
Total
167
—
122
—
10,364
26,359
10,052
26,261
As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2025, goodwill is not allocated
by geographical region.
B.21.4. Disclosures about major customers
Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 42% of
net sales in the first half of 2026. Sanofi’s three largest customers respectively accounted for approximately 22%, 14% and 6% of
consolidated net sales in the first half of 2026 (versus approximately 18%, 12% and 5% in the first half of 2025).
32
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.1
- Condensed half-year consolidated financial statements
B.22. Information related to Opella, presented within discontinued operations
On April 30, 2025, the Opella transaction was closed triggering loss of control, and resulting in the derecognition of all assets and
liabilities of Opella subsidiaries.
The table below shows the main items presented within Net income from discontinued operations:
June 30, 2026
June 30, 2025
Net sales and other revenues (a)
—
1,736
Operating income (a)
—
266
Gain on disposal of Opella before tax
18
2,781
Income before tax and investments accounted for using the equity method, including gain on disposal of Opella
before tax
22
3,039
Income tax expense (b)
4
(158)
Net income from discontinued operations (Opella)
26
2,881
(€ million)
(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.
(b) In 2025, this line includes an expense of €88 million related to the tax impact on the gain arising on the loss of control of Opella.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
33
Exhibit 99.2
TABLE OF CONTENTS
- Half-year management report
35
A/ Significant events of the first half of 2026
35
B/ Progress on implementation of the sustainability strategy
40
C/ Events subsequent to June 30, 2026
41
D/ Consolidated financial statements for the first half of 2026
42
E/ Risk factors and related party transactions
56
F/ Outlook
57
G/ Appendix - research and development pipeline
59
- Statutory auditors’ review report on the half-yearly financial information
61
- Responsibility statement of the certifying officer: half-year financial report
62
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
34
Exhibit 99.2
2. Half-year management report
- Half-year management report
A/ Significant events of the first half of 2026
A.1. First-half overview
During the first half of 2026, Sanofi continued to implement its growth and innovation strategy, focused on launching major
innovations, reallocating resources and developing cutting-edge innovative R&D. Significant events connected with the
implementation of this strategy are described below (for additional information on developments related to Research and
Development see also section "A.2. Research and Development").
On January 29, 2026, Sanofi announced its intention to execute a €1 billion share buyback program in 2026, and on February 2,
2026, it entered into a mandate with an investment services provider for this program. Under the terms of this mandate, Sanofi
was to repurchase its own shares for a maximum amount of €1 billion. The program ended at the end of April 2026.
On February 10, 2026, Sanofi announced that it had completed the acquisition of Dynavax Technologies Corporation (Dynavax).
The acquisition includes Dynavax’s adult hepatitis B vaccine, HEPLISAV-B, currently marketed in the United States, which is
distinguished by its two-dose, one-monthly vaccination schedule. It also includes Dynavax’s shingles vaccine candidate (Z-1018),
currently in phase 1/2 clinical trials, as well as other vaccine projects in development.
On April 24, 2026, Sanofi announced the successful placement of a €2.3 billion bond issue under the Euro Medium Term Note
program. Sanofi will allocate the net proceeds from the issuance of these bonds to general corporate purposes.
Net sales for the first half of 2026 amounted to €22,106 million, 11.1% higher than in the first half of 2025. At constant exchange
rates (CER)(1), net sales rose by 15.7%, driven mainly by strong performances for Dupixent, Ayvakit and ALTUVIIIO.
Net income attributable to equity holders of Sanofi amounted to €1,957 million in the first half of 2026, versus €5,812 million in
the first half of 2025. Earnings per share was €1.63 for the first half of 2026, versus €4.74 for the first half of 2025. Business net
income(2) was €4,765 million, up 14.8% versus the first half of 2025, while business earnings per share (business EPS(2)) was €3.97,
17.1% up versus the first half of 2025.
A.2. Research and development
Sanofi’s research and development (R&D) is focused on developing and delivering life-changing medicines and vaccines that
change the lives of patients for many of the world’s most complex diseases. Progress made in R&D during the first half of 2026 is
described in detail below, and an update on the R&D pipeline is presented in Section G/ of this half-year management report.
Immunology
Dupixent (dupilumab)
After evaluation under priority review, the US Food and Drug Administration (FDA) approved Dupixent for the treatment of adult
and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery.
This approval expands the coverage of sino-nasal diseases with Dupixent to now include AFRS, alongside chronic rhinosinusitis
with nasal polyps (CRSwNP).
The FDA and the European Commission (EC) approved Dupixent for the treatment of children aged two to 11 years with chronic
spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine (H1AH) treatment. These approvals
expand the previous authorizations for Dupixent in adults and adolescents aged 12 years and older with CSU.
The Ministry of Health, Labour and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent
for the treatment of adults with moderate-to-severe bullous pemphigoid (BP). When publishing its first-quarter 2025 results,
Sanofi announced that the European Medicines Agency (EMA) had accepted its Marketing Authorisation Application for
Dupixent in the treatment of BP. Following comments from the EMA during its ongoing review of Dupixent for this indication,
Sanofi has decided to withdraw the application.
The two phase 3 studies of Dupixent in the LIBERTY-LSC clinical program (STYLE 1 and STYLE 2; clinical study identifiers:
NCT06687967 and NCT06687980, respectively) in lichen simplex chronicus (LSC) did not meet their primary endpoints of itch
reduction compared to placebo. The safety data from these studies were generally consistent with the known safety profile of
Dupixent. As a result of this outcome, Sanofi and Regeneron will conduct a thorough analysis of the data and plan to present
them at a forthcoming medical meeting.
(1)
(2)
Non-IFRS financial measure: see definition in D.3., “Net sales”.
Non-IFRS financial measure: see definition in D.2., “Business net income”.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
35
Exhibit 99.2
2. Half-year management report
Rezurock (belumosudil)
The EC granted a conditional marketing authorization for Rezurock for the treatment of chronic graft-versus-host disease
(cGVHD) in adults and children aged 12 years and older with a body weight of at least 40 kg. The medicine is to be used when
other treatment options provide limited clinical benefit, are not suitable, or have been exhausted. This conditional marketing
authorization followed the positive opinion issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in
January, and is contingent on completion of a confirmatory, randomised, controlled study.
Tzield/Teizeild (teplizumab)
In April, the FDA approved the supplemental biologic license application for Tzield, expanding the indication to patients as young
as one year old, compared to a minimum of eight years previously, to delay the onset of stage 3 type 1 diabetes (T1D) in patients
diagnosed with stage 2 T1D. In June, the FDA approved Tzield to delay the decline in endogenous insulin production in children
aged eight to 17 years recently diagnosed with stage 3 T1D. Both approvals were granted under a priority review process.
In the EU, teplizumab was approved (under the name Teizeild) to delay the onset of stage 3 T1D in adults and pediatric patients
aged eight years and older diagnosed with stage 2 T1D.
amlitelimab (OX40L monoclonal antibody)
On July 24, 2026, a decision was made as part of the ongoing strategic assessment of the pipeline that amlitelimab would not
progress to regulatory submission. Sanofi determined that the totality of efficacy and safety evidence generated to date does
not support further development of amlitelimab in atopic dermatitis (AD). While the ESTUARY phase 3 long-term extension study
(clinical study identifier: NCT06407934) showed long-term maintenance of clinical response without relapse in patients aged 12
years and older with moderate-to-severe AD and an emerging safety profile that builds on previous data (including phase 3
studies COAST 1, SHORE and COAST 2; clinical study identifiers: NCT06130566, NCT06224348 and NCT06181435, respectively),
amlitelimab would not represent a meaningful improvement to the standard of care for patients with AD.
itepekimab (IL33 monoclonal antibody)
After complete assessment of the results from AERIFY 1 (clinical study identifier: NCT04701983) and AERIFY 2 (clinical study
identifier: NCT04751487), the two phase 3 studies in chronic obstructive pulmonary disease (COPD) that read out in May 2025,
and after considering the competitive landscape, Sanofi and its collaboration partner Regeneron have decided not to proceed
with development of itepekimab in COPD. As a result, the development programme will be discontinued, including all studies in
chronic rhinosinusitis.
duvakitug (TL1A monoclonal antibody)
Positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug (clinical study identifier: NCT05668013)
showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn’s
disease (CD) that initially responded to the induction phase. RELIEVE UCCD LTE is a double-blind randomised study evaluating
the long-term efficacy, safety, and tolerability of duvakitug in UC and CD. The efficacy data from the LTE study and from the
previous RELIEVE UCCD phase 2b induction study (clinical study identifier: NCT05499130) reinforce the therapeutic potential of
duvakitug in UC and CD, which is under evaluation in phase 3 clinical studies.
lunsekimig (IL13xTSLP Nanobody® VHH)
Phase 2 studies of lunsekimig in two chronic respiratory diseases, moderate-to-severe asthma (AIRCULES phase 2b study;
clinical study identifier: NCT06102005) and CRSwNP (DUET phase 2a proof-of-concept study; clinical study identifier:
NCT06454240), met their primary and key secondary endpoints compared to placebo. The exploratory VELVET phase 2b study
(clinical study identifier: NCT06790121) did not meet its primary endpoint in moderate-to-severe atopic dermatitis. In all studies,
lunsekimig was well tolerated.
frexalimab (CD40L monoclonal antibody)
The FREXERA phase 2/3 study of frexalimab in kidney transplantation (clinical study identifier: NCT07412470) commenced
dosing the first patient in March 2026. The study is testing whether frexalimab dosed subcutaneously (after an initial intravenous
dose) combined with standard-of-care treatment can reduce the risk of rejection of the new kidney, help it last longer, and
improve kidney function.
Rare diseases
Nexviazyme (avalglucosidase alfa)
Nexviazyme met its primary endpoint (participants alive and free of invasive ventilation) in treatment-naive infants aged zero to
six months in the Baby-COMET phase 3 study (clinical study identifier: NCT04910776). In addition, the study met all secondary
endpoints. Sanofi intends to submit the data to support a regulatory application in the US for the treatment of infantile-onset
Pompe disease.
Wayrilz (rilzabrutinib)
In June, the MHLW in Japan granted marketing and manufacturing authorization to Wayrilz for the treatment of persistent or
chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is
36
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
problematic. The approval is based on the LUNA 3 phase 3 study (clinical study identifier: NCT04562766) in which Wayrilz met
the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other symptoms.
Myqorzo (aficamten)
In May, Cytokinetics, Sanofi’s licensor of Myqorzo in China, announced positive topline results from the ACACIA-HCM phase 3
study of Myqorzo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. In the study, all primary
endpoints were met, statistically significant improvements in key secondary endpoints were obtained, and no new safety signals
were identified. The results are expected to form the basis for a regulatory submission in China in 2027.
Redemplo (plozasiran)
In China, Redemplo was granted a breakthrough designation in severe hypertriglyceridemia. Redemplo will be marketed in
Greater China by Sanofi under an agreement with Arrowhead. In 2025, Sanofi purchased those rights from Visirna, a majority
owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead’s cardiometabolic pipeline medicines
in Greater China. Sanofi plans to initiate launch of Redemplo in the near future for the reduction of triglyceride levels in adult
patients with familial chylomicronaemia syndrome (FCS), a severe and rare disease leading to a substantially higher risk of
developing acute, recurrent, and potentially fatal pancreatitis.
venglustat (oral glucosylceramide synthase inhibitor)
In May, the FDA granted priority review to the new drug application (NDA) for venglustat for the treatment of type 3 Gaucher
disease (GD3), a rare lysosomal storage disorder. If approved, venglustat would become the first treatment available in the US to
address the progressive neurological manifestations associated with GD3 and expand Sanofi’s portfolio of treatment options for
patients living with lysosomal storage diseases. The target action date for the FDA decision is November 25, 2026. In Fabry
disease, venglustat did not meet the primary endpoint in the PERIDOT and CARAT phase 3 studies (clinical study identifiers:
NCT05206773 and NCT05280548, respectively). The long-term extensions of the PERIDOT and CARAT studies are both
continuing.
efdoralprin alfa (alpha-1 antitrypsin fusion protein)
Data from the global ElevAATe phase 2 study (clinical study identifier: NCT05856331) demonstrated superiority of efdoralprin
alfa over standard-of-care therapy in achieving and maintaining normalized functional alpha-1 antitrypsin levels in adult patients
with alpha-1 antitrypsin deficiency (AATD)-related emphysema. Additional long-term safety and efficacy outcomes are being
evaluated in the ElevAATe OLE phase 2 study (clinical study identifier: NCT05897424). Efdoralprin alfa is a recombinant protein
distinct from plasma-derived therapy, which has been the standard-of-care for nearly 40 years. It has been granted fast track
designation and orphan drug designation in the US and orphan designation in the EU. A first regulatory submission in the US is
expected in the second half of 2026, depending on final regulatory feedback.
Neurology
Cenrifki (tolebrutinib)
In June, the EC approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the
last two years. This approval followed the positive opinion by the EMA's CHMP and was based on the HERCULES phase 3 study
(clinical study identifier: NCT04411641) in non-relapsing SPMS (nrSPMS), with supporting data from GEMINI 1 and GEMINI 2 phase
3 studies in relapsing multiple sclerosis (clinical study identifiers: NCT04410978 and NCT04410991, respectively). The HERCULES
study demonstrated that Cenrifki significantly delayed the onset of disability progression in nrSPMS.
riliprubart (C1s monoclonal antibody)
In June, Sanofi announced discontinuation of the MOBILIZE phase 3 study (clinical study identifier: NCT06290128) of riliprubart
in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment. This
decision followed an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study
was unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim analysis.
The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier:
NCT06290141) in IVIg-treated patients with CIDP, has been evaluated accordingly. The VITALIZE study continues as planned.
Oncology
Sarclisa (isatuximab)
The EC (in June) and the FDA (in July) approved subcutaneous (SC) Sarclisa / Sarclisa Escena (the US product name) in
combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing
indications for Sarclisa intravenous (IV) formulation. Sarclisa/ Sarclisa Escena is the first anticancer therapy to be administered
through an on-body injector (OBI) and the first MM treatment available by both SC OBI and manual administration in the EU and
the US, thereby providing flexibility of administration at patients’ homes and in an outpatient setting. Sarclisa / Sarclisa Escena
can be used in conjunction with Enable Injections’ CirCLIQ OBI, enabling it to be delivered subcutaneously with the push of a
button using a shorter, thinner retractable needle. Sarclisa SC formulation in combination with approved standard-of-care
regimens for the treatment of MM was also approved by the MHLW in Japan. A regulatory submission for Enable Injections’
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
37
Exhibit 99.2
2. Half-year management report
CirCLIQ OBI is under review in Japan. An application for Sarclisa SC administered via manual injection is currently under review in
China.
Vaccines
Nuvaxovid (COVID-19)
Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower
systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE
(mRNA-1283), Moderna's latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study (clinical
study identifier: NCT07051031), which enrolled 1,000 adults in the US.
Fluzone HD/Efluelda (influenza)
The FDA and EMA accepted for review the regulatory submission of Fluzone high dose (HD)/Efluelda for use in adults aged 50
years and above to prevent influenza. The regulatory submission follows positive results in the QHD00042 phase 3 study (clinical
study identifier: NCT06641180) reported in October 2025.
A.3. Other significant events
A.3.1 Corporate governance
The Combined General Shareholders’ Meeting of Sanofi was held on April 29, 2026 at the Palais des Congrès in Paris, and was
chaired by Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. Decisions taken by the
General Meeting included approving the individual company and consolidated financial statements for the year ended
December 31, 2025, and distributing an ordinary annual dividend of €4.12 per share.
Board of Directors
Sanofi’s Board of Directors met on February 11, 2026, and decided not to renew Paul Hudson’s term of office as a director.
Consequently, on February 18, 2026, Paul Hudson resigned from his position as a director, with immediate effect.
The Combined General Shareholders’ Meeting of Sanofi held on April 29, 2026 approved the reappointments of Jean-Paul Kress
as an independent director and Christophe Babule as a director, and the appointments of Belén Garijo as a director and Christel
Heydemann as an independent director. Following the expiry of Patrick Kron’s term of office at the close of the Annual General
Meeting of April 29, 2026, the Board of Directors now comprises 16 members, of whom eight are women and two are directors
representing employees. The Board of Directors retains a large majority of independent directors.
Following the departure of Paul Hudson and Patrick Kron from the board of directors, and on the proposal of the Appointments,
Governance and CSR Committee, the Board of Directors appointed Frédéric Oudéa as Chairman of the Appointments,
Governance and CSR Committee; Belén Garijo as a member of the Strategy Committee; and Christel Heydemann as a member
of the Appointments, Governance and CSR Committee and the Compensation Committee.
Chief Executive Officer
The Board of Directors relieved Paul Hudson of his duties as Chief Executive Officer effective end-of-day on February 17, 2026.
Olivier Charmeil (Executive Vice-President, General Medicine), served as Interim Chief Executive Officer from February 18 until
April 30, 2026.
The Board meeting held on April 29, 2026 confirmed the appointment of Belén Garijo as Chief Executive Officer of Sanofi with
effect from May 1, 2026.
Executive Committee
In the first half of 2026, the Executive Committee's composition changed with:
• the departure of Paul Hudson as Chief Executive Officer effective end-of-day on February 17, 2026, and the appointment of
Belén Garijo to succeed him, effective May 1, 2026;
• the appointment of Manuela Buxo as Executive Vice President, Specialty Care, effective March 1, 2026. Manuela Buxo
succeeded Brian Foard, who decided to leave the company as of February 28, 2026, having accepted an external leadership
opportunity; and
• the departure of Natalie Bickford from her position as Executive Vice President, Chief People Officer on May 31, 2026.
Véronique Jaillet is currently serving as interim Chief People Officer with effect from June 1, 2026.
On July 21, 2026 Sanofi announced an evolution of its Executive Committee, which effective September 1, 2026 will comprise:
• François Roger, Executive Vice President, Finance;
38
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
•
•
•
•
•
•
•
Paulo Fontoura, Executive Vice President, Head of Research & Development;
Manuela Buxo, Executive Vice President, Specialty Care;
Thomas Triomphe, Executive Vice President, Vaccines;
Thomas Grenier, Executive Vice President, General Medicines;
Brendan O’Callaghan, Executive Vice President, Manufacturing & Supply;
Jamie Haney, Executive Vice President, General Counsel; and
Véronique Jaillet, Executive Vice President, Interim Chief People Officer.
A.3.2. Legal and arbitration proceedings
For a description of the most significant developments in legal and arbitration proceedings since publication of the financial
statements for the year ended December 31, 2025, refer to Note B.14. to our condensed half-year consolidated financial
statements.
Government Investigations and Related Litigation
In the insulin-related antitrust suit brought on behalf of direct purchasers in Massachusetts Federal Court, trial is scheduled to
begin in January 2027.
In the complaint filed in 2024 by the Texas state court alleging violations of the Texas Medicaid Fraud Prevention Act (TMFPA),
on February 13, 2026, the State of Texas filed its Petition in Intervention asserting a false certification theory of liability. Sanofi
moved to disqualify one of relator's law firms with a hearing expected in August 2026. Discovery closes on January 15, 2027; trial
is scheduled for July 19, 2027 — both dates are subject to continuance pending the court's ruling on the disqualification motion.
A.3.3. Other events
On June 4, 2026, Sanofi announced the launch of Action 2026, a global employee share ownership plan open to around 75,000
employees in 52 countries. Now in its twelfth year, the program demonstrates the ongoing commitment of Sanofi and its Board
of Directors to ensuring that employees benefit from the company’s growth and success.
The shares were offered at a subscription price of €59.87, representing a 20% discount to the average of the 20 opening prices
of Sanofi shares from May 6 to June 2, 2026. For every five shares subscribed, employees were entitled to receive one free share
(up to a maximum of four free shares per employee). Every eligible employee was able to purchase up to 1,500 Sanofi shares,
subject to the maximum legal limit set at 25% of their gross annual salary, minus any voluntary deductions already made under
employee savings schemes such as the Company Savings Plan and/or Group Savings Plan and/or Group Retirement Savings Plan
(PERCO) during 2026; the above limit does not apply to voluntary contributions to the “PERCOL” retirement savings plan.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
39
Exhibit 99.2
2. Half-year management report
B/ Progress on implementation of the sustainability strategy
Acoziborole positive opinion marks major step forward in sleeping sickness elimination
The CHMP granted a positive opinion on acoziborole, a single-dose oral medicine administered as three tablets, positioning it as
a significant advance in supporting the WHO goal of eliminating the disease by 2030.
Sanofi’s commitment – alongside its long-term partner Drugs for Neglected Diseases initiative, the WHO, and other global health
players – has resulted in a 98% reduction in sleeping sickness cases since 2001. Sanofi will donate acoziborole to the WHO
through its philanthropic arm, Sanofi Foundation, ensuring patients receive the treatment at no cost.
Sanofi-supported study quantifies environmental and socio-economic factors exacerbating respiratory
diseases
Sanofi’s sustainability strategy is built on the ambition to tackle the link between environmental challenges, health, and
healthcare.
A study supported by Sanofi, in partnership with Regeneron, analysed health data from over 710,000 asthma and COPD
patients(1) in France between 2018 and 2022, incorporating environmental and socio-economic indicators to identify risk and
protective factors associated with respiratory disease exacerbation.
The study results show that the setting and living conditions directly influence the severity of respiratory diseases. Urban living
increases the risk of exacerbations by 40% in people with asthma, by 53% in asthmatic children, and by 8% in people with COPD.
Conversely, certain natural environments, such as proximity to a forest or other green areas or bodies of water, reduce risk by 5%
and 20%, respectively. The study also confirmed the central role of air pollution in the worsening of respiratory diseases. Other
factors, such as tobacco use and extreme temperatures (increasingly frequent in the context of climate change), also increase
the risk of exacerbations. Additionally, socio-economic inequalities compound environmental risks, with patients in high-poverty
areas facing up to 36% higher exacerbation risk.
GHU progress on access and healthcare system strengthening
Sanofi’s Global Health Unit (GHU) aims to provide access to a broad portfolio of medicines in countries with the highest unmet
medical needs. To that end, the GHU offers Impact: a not-for-profit brand of WHO-essential, standard-of-care medicines
produced by Sanofi.
The Impact medicines portfolio is now available in 30 countries(2) and marks a significant step in expanding access to quality
medicines in underserved regions globally. This milestone reflects the GHU's operational progress and supports the trajectory
toward reaching two million patients with non-communicable diseases (NCDs) treatments by 2030.
The GHU is also strengthening healthcare systems across 40 underserved countries through strategic partnerships, reaching 6.6
million beneficiaries – of whom 6.5 million were screened for NCDs, 1.1 million diagnosed, and nearly 500,000 linked to care
(medical treatment, monitoring, support services, etc.). In parallel, over 40,000 healthcare professionals and community health
workers have been trained, and more than 1,000 pharmacies, distributors, and clinics supported to improve supply chain
efficiency.
AccesS diabetes programme expands to South Africa and India
Sanofi's AccesS Diabetes programme addresses potential barriers to diabetes care by providing patient support initiatives,
capacity and capability building, and high-quality analogue insulin through partnerships with governments and stakeholders
tailored to country-specific needs.
Sanofi signed two new memoranda of understanding in South Africa and India (State of Madhya Pradesh), marking a significant
expansion of its diabetes access initiatives in regions with substantial unmet medical needs. In Madhya Pradesh, the program also
aims to strengthen the infrastructure for diagnosis and treatment of rare diseases.
The AccesS Diabetes program has now been rolled out in Ghana, Nigeria (States of Delta and Kano), South Africa and India (State
of Madhya Pradesh).
The Democratic Republic of the Congo approves acoziborole: the first single-dose treatment for
sleeping sickness
Building on the positive EMA opinion in the first quarter of 2026, the Democratic Republic of the Congo has approved
acoziborole, a breakthrough single-dose oral treatment. Following successful clinical studies in the DRC and Guinea, this
registration marks an important step forward in the fight against gambiense human African trypanosomiasis.
Sustainability dashboard for the second quarter of 2026
Please refer to the sustainability dashboard provided as an appendix to the Sanofi second-quarter 2026 results press release.
(1)
(2)
Study conducted using data from the National Health Data System, specifically hospital data.
Through registration or import licenses.
40
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
C/ Events subsequent to June 30, 2026
The main events related to research and development that occurred between the end of the reporting period and the date on
which the condensed consolidated financial statements were reviewed by the Board of Directors are described in section 'A.2.
Research and Development'. No other significant events occurred during this period.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
41
Exhibit 99.2
2. Half-year management report
D/ Consolidated financial statements for the first half of 2026
Unless otherwise indicated, all financial data in this report are presented in accordance with international financial reporting
standards (IFRS), including international accounting standards and interpretations (see Note A.1. to our condensed half-year
consolidated financial statements).
Consolidated income statements for the six months ended June 30, 2025
and June 30, 2026
(€ million)
June 30, 2026
(6 months)
as % of net sales
June 30, 2025
(6 months)
as % of net sales
Net sales
22,106
100.0%
19,889
100.0%
Other revenues
1,438
6.5%
1,452
7.3%
Cost of sales
(6,155)
-27.8 %
(5,881)
-29.6 %
Gross profit
17,389
78.7%
15,460
77.7%
Research and development expenses
(3,980)
-18.0 %
(3,717)
-18.7 %
Selling and general expenses
(4,792)
-21.7 %
(4,506)
-22.7 %
Other operating income
800
533
Other operating expenses
(3,436)
(2,476)
Amortization of intangible assets
(1,087)
(777)
Impairment of intangible assets
(1,031)
(210)
Fair value remeasurement of contingent consideration
(37)
(61)
Restructuring costs and similar items
(563)
(430)
Other gains and losses, and litigation
(57)
(95)
3,168
Financial expenses
(465)
(361)
Financial income
137
184
Income before tax and investments accounted for using the equity
method
Income tax expense
Share of profit/(loss) from investments accounted for using the equity
method
2,840
14.3%
3,759
Operating income
12.8%
3,582
(871)
(711)
2
85
18.9%
18.0%
Net income from continuing operations
1,971
8.9%
2,956
14.9%
Net income from discontinued operations
26
0.1%
2,881
14.5%
1,997
9.0%
5,837
29.3%
Net income
Net income attributable to non-controlling interests
Net income attributable to equity holders of Sanofi
40
1,957
25
8.9%
5,812
Average number of shares outstanding (million)
1,200.4
1,225.5
Average number of shares after dilution (million)
1,205.5
1,230.7
2.40
•
Basic earnings per share from continuing operations (€)
1.61
•
Basic earnings per share from discontinued operations (€)
0.02
2.34
1.63
4.74
Basic earnings per share (in euros)
•
Diluted earnings per share from continuing operations (€)
1.60
2.39
•
Diluted earnings per share from discontinued operations (€)
0.02
2.33
1.62
4.72
Diluted earnings per share (in euros)
42
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
29.2%
Exhibit 99.2
2. Half-year management report
D.1. Segment information
D.1.1. Operating segments
In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of
internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The
performance of the single operating segment is monitored individually using internal reports and common indicators. The
operating segment disclosures required under IFRS 8 are provided in Note B.21. to our condensed half-year consolidated
financial statements.
The segment information presented by Sanofi consists of a single operating segment: Biopharma.
The Biopharma operating segment comprises commercial operations and research, development and production activities
relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all
geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced
to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date,
corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier & Rice
(CD&R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing
operations, are presented within Other revenues in the income statement. The Biopharma operating segment also includes the
purchase price of Biopharma products manufactured by Opella.
The “Other” category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective
date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be
finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital
(Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with
the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution
agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained
subsidiary Gold Bond LLC (holder of the associated worldwide property rights).
D.1.2. Business operating income
We report segment results on the basis of “Business operating income”. This indicator is used internally by Sanofi’s chief
operating decision maker to measure the performance of the operating segment and to allocate resources. For a definition of
“Business operating income” refer to Note B.21.1. to our condensed half-year consolidated financial statements.
“Business operating income” is a non-IFRS financial measure and is reconciled with IFRS Operating income. In the first half of
2026, Operating income amounted to €3,168 million, versus €3,759 million in the first half of 2025, and our “Business operating
income” amounted to €6,258 million, versus €5,363 million in the first half of 2025. The reconciliation between these two
measures is presented in the table below.
Because our “Business operating income” is not a standardized measure, it may not be directly comparable with the non-IFRS
financial measures of other companies using the same or similar non-IFRS financial measures. Although management uses this
non-IFRS measure to set goals and measure performance, it has no standardized meaning prescribed by IFRS. This non-IFRS
measure is presented solely to permit investors to more fully understand how Sanofi’s management assesses underlying
performance. This non-IFRS measure is not, and should not be viewed as, a substitute for IFRS measures, and should be viewed
in conjunction with IFRS measures of our performance and financial position. Consequently, there may be limitations on the
usefulness of this measure to investors.
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Operating income
3,168
3,759
Other gains and losses, and litigation (a)
(95)
(57)
Restructuring costs and similar items (b)
(563)
(430)
Expenses resulting from acquisition-related impacts on inventories (c)
(210)
0
Fair value remeasurement of contingent consideration
(37)
(61)
(€ million)
Impairment of intangible assets (d)
(1,031)
(210)
Amortization of intangible assets
(1,087)
(777)
Net income attributable to non-controlling interests (e)
Share of profit/(loss) from investments accounted for using the equity method (f)
Business operating income
7
8
(74)
(77)
6,258
5,363
(a) See Note B.17. (“Other gains and losses, and litigation”) to the condensed half-year consolidated financial statements.
(b) See Note B.16. (“Restructuring costs and similar items”) to the condensed half-year consolidated financial statements.
(c) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026
relate to the Blueprint Medicines and Dynavax acquisitions.
(d) The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €1,031 million in the first half of 2026
mainly comprising a €952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly
comprises impairment losses of €210 million linked to research and development projects.
(e) Excluding restructuring costs and other adjusted items attributable to non-controlling interests.
(f) Primarily joint ventures.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
43
Exhibit 99.2
2. Half-year management report
D.2. Business net income (non-IFRS financial measure)
Sanofi also presents “Business net income”, a non-IFRS financial measure which is not defined by accounting standards and is
not included in the primary financial statements.
The IFRS measure most directly comparable to “Business net income” is Net income attributable to equity holders of Sanofi,
which amounted to €1,957 million in the first half of 2026, versus €5,812 million in the first half of 2025, representing a decrease
of 66.3%. “Business net income” amounted to €4,765 million in the first half of 2026, versus €4,152 million in the first half of
2025, representing an increase of 14.8%. “Business net income” in the first half of 2026 represents 21.6% of our net sales,
compared with 20.9% of our net sales in the first half of 2025.
We also report “Business earnings per share” (business EPS), a non-IFRS financial measure which we define as business net
income divided by the weighted average number of shares outstanding. Business EPS was €3.97 for the first half of 2026 (up
17.1%) compared with the 2025 first-half figure of €3.39, based on an average number of shares outstanding of €1,200 million for
the first half of 2026 and €1,225 million for the first half of 2025.
We define “Business net income” as Net income attributable to equity holders of Sanofi determined under IFRS, excluding the
following items:
• net income from discontinued operations, including Opella;
• amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or
operational nature);
• fair value remeasurements of contingent consideration relating to business combinations (IFRS 3), or to divestments of
operations meeting the definition of a business;
• expenses arising from the remeasurement of inventories following business combinations (IFRS 3) or acquisitions of groups of
assets that do not constitute a business within the meaning of paragraph 2b of IFRS 3;
• restructuring costs and similar items (presented within the line item Restructuring costs and similar items);
• other gains and losses (including gains and losses on major divestments), presented within the line item Other gains and
losses, and litigation;
• other costs and provisions related to litigation (presented within the line item Other gains and losses, and litigation);
• (income)/expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in
accordance with paragraph B5.4.6 of IFRS 9 (Financial Instruments);
• the share of profits/losses from investments accounted for using the equity method, except to the extent that this relates
(i) to joint ventures or (ii) to associates with which Sanofi has entered into R&D agreements and/or whose operations are
managed as an integral part of Sanofi’s business activities; and
• the portion attributable to non-controlling interests of the items listed above.
The table below reconciles Net income attributable to equity holders of Sanofi to our “Business net income” :
44
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
June 30, 2026
(6 months)
(€ million)
June 30, 2025
(6 months)
Net income attributable to equity holders of Sanofi (IFRS)
1,957
5,812
Net (income)/loss from the discontinued Opella business (a)
(26)
(2,881)
Amortization of intangible assets
1,087
777
Impairment of intangible assets
1,031
210
Fair value remeasurement of contingent consideration
70
68
Expenses arising from the impact of acquisitions on inventories
210
—
Restructuring costs and similar items
563
430
Other gains and losses, and litigation(c)
95
57
Financial (income)/expenses relating to financial liabilities accounted for at amortized cost and subject to
periodic remeasurement(d)
146
50
Tax effects of the items listed above:
(423)
(384)
•
amortization and impairment of intangible assets
(198)
(173)
•
fair value remeasurement of contingent consideration
(6)
(14)
•
expenses arising from the impact of acquisitions on inventories
(47)
—
•
tax effects of restructuring costs and similar items
(89)
(113)
•
(b)
other items
(83)
(84)
Other tax effects
(17)
11
Other items (e)
72
2
Business net income (non-IFRS)
4,765
4,152
Average number of shares outstanding (million)
1,200.4
1,225.5
Basic earnings per share (IFRS) (in euros)
1.63
4.74
Reconciling items per share (in euros) (f)
2.34
(1.35)
Business earnings per share (non-IFRS) (in euros)
3.97
3.39
(a) In 2026, this line mainly comprises the impact of the finalization of the Opella completion accounts as of April 30, 2025. In 2025, this line item includes
€2,693 million related to the net gain resulting from the sale of Opella at the date of loss of control (see Note B.1. to the 2025 consolidated financial
statements as presented in Sanofi’s 2025 Half year report).
(b) The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €1,031 million in the first half of 2026
mainly comprising a €952 million impairment loss taken against the amlitelimab asset..For the six months ended June 30, 2025, this line mainly
comprises impairment losses of €210 million linked to research and development projects.
(c) For the first half of 2026, Other gains and losses, and litigation represents a charge of €95 million mainly related to major litigation, compared with a
charge of €57 million in the first half of 2025.
(d) This line item represents the financial expense arising from remeasurement of the liability recognized in the balance sheet for estimated future royalties
payable on Beyfortus sales in the United States.
(e) Other items include Sanofi’s share of losses from the associates EUROAPI and OPAL JV Co (Opella).
(f) Represents the reconciliation between basic earnings per share (IFRS) and business earnings per share (non-IFRS): total reconciling items divided by the
weighted average number of shares outstanding.
The most significant reconciling items between “Business net income” and Net income attributable to equity holders of
Sanofi relate to (i) the purchase accounting effects of our acquisitions of groups of assets and business combinations,
particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or
operational nature); (ii) the impacts of restructuring actions or transactions regarded as non-recurring, where the amounts
involved are particularly significant; (iii) the remeasurements recognized through profit or loss in respect of (a) amounts
receivable in respect of business divestments and accounted for at fair value, (b) liabilities arising from business combinations
(IFRS 3) and accounted for at fair value, (c) liabilities accounted for at amortized cost and subject to periodic remeasurement
under IFRS 9; and (iv) the net income from discontinued operations, including Opella. We believe that excluding those impacts
enhances an investor’s understanding of our underlying economic performance, because it gives a better representation of our
recurring operating performance.
We believe that eliminating charges related to purchase accounting effects (particularly amortization and impairment of some
intangible assets) enhances comparability of our ongoing operating performance relative to our peers. Those intangible assets
(principally rights relating to research and development, technology platforms and commercialization of products) are
accounted for in accordance with IAS 38 (Intangible Assets) and IFRS 3 (Business Combinations).
We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from
the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our
recurring operating performance.
Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in
connection with reorganization and transformation Company’s programs, integration or separation as part of material deals.
We believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant
amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major
non-recurring items) improves comparability from one period to the next.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
45
Exhibit 99.2
2. Half-year management report
Finally, remeasurements recognized in profit or loss during the period in respect of (i) assets or liabilities accounted for at fair
value and recognized in the balance sheet in connection with business acquisitions or divestments or (ii) liabilities accounted for
at amortized cost and subject to periodic remeasurement, generally determined on the basis of revised sales forecasts, are not
reflective of our operating performance.
In addition, “Business net income” excludes net income from the Opella discontinued operation, the results of which have been
presented separately in the consolidated income statement since October 2024. Under IFRS 5 (Non-Current Assets Held for
Sale and Discontinued Operations), a discontinued operation is defined as a component of an entity that has been disposed of or
is classified as held for sale, and represents a separate major line of business.
With effect from October 2024, “Business net income” from continuing operations is used by management to measure Sanofi’s
financial performance on an ongoing basis. We believe that providing a performance measure aligned with our management
approach is useful for investors and analysts.
We remind investors, however, that “Business net income” should not be considered in isolation from, or as a substitute for, Net
income attributable to equity holders of Sanofi reported in accordance with IFRS. In addition, we strongly encourage
investors and potential investors not to rely on any single financial measure but to review our financial statements, including the
notes thereto, carefully and in their entirety.
We compensate for the material limitations described above by using “Business net income” only to supplement our IFRS
financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments
included in “Business net income.”
Because our “Business net income” and “Business EPS” are not standardized measures, they may not be directly comparable
with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures.
D.3. Net sales
Net sales for the first half of 2026 amounted to €22,106 million, 11.1% higher at published exchange rates than in the first half of
2025. Exchange rate fluctuations had a negative effect of 4.6 percentage points overall, due mainly to adverse trends in the
euro exchange rate against the US dollar. At constant exchange rates (CER, see definition below), net sales rose by 15.7%, driven
mainly by strong performances for Dupixent, Ayvakit and ALTUVIIIO. Divestments and medicines/portfolio streamlining had a
negative impact of 0.4 percentage points on sales growth.
Reconciliation of net sales (IFRS) to net sales at constant exchange rates (non-IFRS)
(€ million)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Change
Net sales
22,106
19,889
+11.1%
19,889
+15.7%
(905)
Effect of exchange rates
23,011
Net sales at constant exchange rates
When we refer to changes in our net sales at constant exchange rates (CER), that means we have excluded the effect of
exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous
period, with the exception of countries treated as hyperinflationary economies under IAS 29 (i.e. Argentina and Turkey, see Note
A.4 to our condensed half-year consolidated financial statements).
D.3.1. Net sales by segment
Our net sales comprise the net sales generated by our Biopharma segment.
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Change on
a reported
basis
Change at
constant
exchange rates
Biopharma segment
22,106
19,889
+11.1%
+15.7%
Total net sales
22,106
19,889
+11.1%
+15.7%
(€ million)
46
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
D.3.2. Net sales by medicine, vaccine and geography
Net sales by main product and geographical region break down as follows:
(€ million)
Change
Total sales (reported)
Change
(CER)
United
States
Change
(CER)
Europe
Change
Rest of
(CER) the world
Change
(CER)
Immunology
Dupixent
9,324
+27.5%
+34.4%
6,922
+39.5%
1,146
+20.9%
1,256
+20.8%
Kevzara
301
+22.9%
+28.6%
207
+45.7%
73
+10.8%
21
-20.7%
ALTUVIIIO (*)
674
+24.4 %
+32.3 %
576
+34.4 %
—
—%
98
+20.9 %
Fabrazyme
523
-0.4 %
+4.0 %
256
+4.6 %
138
+2.2 %
129
+4.6 %
Nexviazyme/Nexviadyme (*)
426
+10.1 %
+14.5 %
211
+15.4 %
152
+15.2 %
63
+10.0 %
Rare diseases
Ayvakit (*)
367
—%
—%
322
—%
44
—%
1
—%
Cerezyme
352
-3.0 %
-1.7 %
86
+1.1 %
126
+5.0 %
140
-8.5 %
Alprolix
282
-7.5 %
-1.6 %
215
-4.2 %
—
—%
67
+7.7 %
Myozyme
220
-20.0 %
-18.2 %
77
-9.9 %
62
-36.1 %
81
-6.9 %
Cerdelga
183
+10.2 %
+14.5 %
101
+21.3 %
74
+7.4 %
8
—%
Cablivi (*)
153
+12.5 %
+16.2 %
87
+29.6 %
58
+5.5 %
8
-20.0 %
Aldurazyme
147
-9.8 %
-7.4 %
36
+8.3 %
44
+2.3 %
67
-19.0 %
Eloctate
142
+5.2 %
+12.6 %
77
-14.4 %
—
—%
65
+81.6 %
Xenpozyme (*)
127
+15.5 %
+18.2 %
47
+6.4 %
44
—%
36
+89.5 %
Wayrilz (*)
27
—%
—%
27
—%
—
—%
—
—%
Qfitlia (*)
12
+1100.0 %
+1200.0 %
12
+1200.0 %
—
—%
—
—%
Myqorzo (*)
3
—%
—%
—
—%
—
—%
3
—%
Sarclisa (*)
354
+28.3 %
+33.0 %
132
+17.6 %
108
+30.1 %
114
+60.8 %
Jevtana
136
-3.5 %
+4.3 %
94
-6.5 %
1
-50.0 %
41
+45.2 %
-0.9 %
Oncology
Other medicines
Lantus
813
-7.2 %
-3.8 %
344
-6.6 %
146
-2.7 %
323
Toujeo
729
+5.3 %
+7.5 %
134
+14.3 %
259
+3.6 %
336
+7.9 %
Plavix
440
-7.0 %
-4.4 %
2
—%
40
-9.1 %
398
-4.0 %
Lovenox
364
-18.6 %
-19.2 %
5
-44.4 %
202
-19.4 %
157
-17.8 %
Praluent
317
+18.7 %
+18.4 %
—
—%
265
+25.8 %
52
-8.6 %
Rezurock (*)
296
+12.5 %
+18.3 %
218
+5.5 %
36
+60.9 %
42
+110.0 %
Thymoglobulin
257
+3.6 %
+8.5 %
157
+7.8 %
20
-4.8 %
80
+13.7 %
Aprovel
218
+2.8 %
+4.2 %
1
-66.7 %
33
-5.7 %
184
+7.5 %
Soliqua/iGlarLixi
165
+21.3 %
+24.3 %
53
+27.3 %
24
-3.8 %
88
+33.3 %
Multaq
151
-5.6 %
+0.6 %
137
+1.4 %
5
—%
9
-10.0 %
Apidra
140
—%
+1.4 %
2
-60.0 %
51
-3.8 %
87
+8.4 %
Synvisc
93
-18.4 %
-16.7 %
59
-7.4 %
9
—%
25
-37.8 %
Tzield (*)
37
+27.6 %
+34.5 %
32
+25.9 %
4
+300.0 %
1
—%
Other
1,700
-13.2 %
-11.8 %
162
-29.4 %
514
-13.5 %
1,024
-7.3 %
190
-24.3 %
-21.9 %
7
+700.0 %
181
-22.4 %
2
-88.9 %
Polio/pertussis/Hib primary vaccines
and boosters, incl. Heplisav-B (*)
1,364
+0.2 %
+2.8 %
487
+61.3 %
206
-7.6 %
671
-17.2 %
Meningitis, travel, and endemic vaccines
565
-7.2 %
-3.9 %
268
-11.0 %
118
+22.9 %
179
-5.7 %
RSV vaccines (Beyfortus) (*)
392
+10.1 %
+13.2 %
65
+2.9 %
87
+2.4 %
240
+21.2 %
-34.3 %
Industrial sales
Vaccines
Influenza, COVID-19 vaccines (*)
121
-43.5 %
-42.1 %
16
-64.8 %
33
-34.6 %
72
Biopharma
22,106
+11.1%
+15.7%
11,633
+29.9%
4,304
+3.6%
6,169
+1.9%
Of which launches (*)
3,047
45.1 %
51.8 %
1,891
+66.9 %
546
+29.6 %
610
+33.2 %
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
47
Exhibit 99.2
2. Half-year management report
D.3.3. Biopharma segment
In the first half of 2026, revenue from the Biopharma business (see “Chapter D.1. Segment Information” for detailed segment
information) was €22,106 million, up 11.1% on a reported basis and 15.7% at constant exchange rates (CER), driven by Dupixent
and new launches.
Comments on the performances of our major Biopharma segment products are provided below.
Immunology
Dupixent (atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRcNP), eosinophilic esophagitis, nodular
prurigo (NP), chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD), bullous pemphigoid and
allergic fungal rhinosinusitis (AFRS)) generated net sales of €9,324 million in the first half of 2026, up 27.5% on a reported basis
and 34.4% CER. This growth was driven by strong volume increases across all approved indications, with Dupixent maintaining a
leading market position in all its therapeutic indications. In the United States, sales of Dupixent reached €6,922 million in the first
half of 2026, up 39.5% CER, driven primarily by strong demand as well as operational improvements and a favorable change in
estimated gross-to-net deductions. In Europe, the product’s net sales for the first half of 2026 totaled €1,146 million, up 20.9%
CER, reflecting continued momentum in all approved indications and consistent performances in the larger markets, including
Germany. In the Rest of the World region, Dupixent posted net sales of €1,256 million (+20.8% CER), mainly supported by Brazil
and Canada.
Sales of Kevzara (rheumatoid arthritis, other rheumatological indications) amounted to €301 million, representing an increase of
28.6% CER. The majority of sales (€207 million) was generated in the United States (+45.7% CER), mainly due to increased use in
the treatment of polymyalgia rheumatica, an indication approved in 2024.
Rare diseases
ALTUVIIIO (hemophilia A) generated sales of €674 million in the first half of 2026, with 85.5% of those sales coming from the
United States. This performance reflects the transition of patients away from conventional short-acting factor replacement
therapies, and to a lesser extent from other non-factor medicines. Sales in the Rest of the World region totaled €98 million,
benefiting from launches in Japan and Taiwan. Sales of the factor replacement drug franchise for the treatment of hemophilia A
(ALTUVIIIO and Eloctate combined) reached €816 million (+28.4% CER compared with the first half of 2025), driven primarily by
the sustained commercial performance of ALTUVIIIO and geographical launches. Eloctate generated €142 million in revenue in
the first half of 2026, up 12.6% CER, reflecting the transition of patients to ALTUVIIIO.
Sales of the Fabry disease treatment Fabrazyme reached €523 million in the first half of 2026 (+4.0% CER), mainly from
increased patient use and price increases in the United States.
Nexviazyme/Nexviadyme (Pompe disease) generated revenue of €426 million, up 14.5% CER, driven by 15.2% CER growth in
Europe, where the transition of patients from Myozyme/Lumizyme continues. In the United States, growth reached 15.4% CER,
with most patients having already made this transition. Sales of the Pompe disease franchise (Nexviazyme/Nexviadyme and
Myozyme/Lumizyme) totaled €646 million, up 0.9% CER, with Nexviazyme/Nexviadyme now representing 65.9% of the
franchise's revenue.
Sales of Ayvakit (systemic mastocytosis) totaled €367 million. These sales were mainly distributed across the United States
(€322 million) and Europe (€44 million), with continued growth in the number of patients treated and their duration of treatment.
The integration of Blueprint into Sanofi resulted in increased rebates granted to public authorities in the United States,
negatively impacting sales. Without these increased rebates in the United States, revenue growth would have been
approximately nine percentage points higher. Royalties on sales by CStone Pharmaceuticals in China are recorded in Other
revenues.
Sales of Cerezyme decreased by 1.7% CER to €352 million. Growth in Europe (+5.0% CER) and the United States (+1.1% CER) was
offset by lower sales in the Rest of the World region (-8.5% CER). Sales for the Gaucher disease franchise (Cerezyme and
Cerdelga combined) amounted to €535 million.
In the first half of 2026, sales of Alprolix amounted to €282 million, down 1.6% CER, driven by a decline in the United States
(-4.2%) offset by higher sales in the Rest of the World region (which includes sales of supplies to Sanofi’s collaboration partner
Sobi).
Sales of Myozyme/Lumizyme decreased by 18.2% CER in the first half of 2026 to €220 million, due to the ongoing shift to
Nexviazyme/Nexviadyme as mentioned above.
Sales of Cablivi (acquired thrombotic thrombocytopenic purpura) reached €153 million (+16.2% CER) in the first half of the year,
driven by an increase in the number of patients treated in the United States (where sales rose by 29.6% CER) and Europe (+5.5 %
CER). In the Rest of the World region, sales totaled €8 million (-20.0% CER).
Sales of Xenpozyme (acid sphingomyelinase deficiency) increased to €127 million in the first half, up 18.2% CER, mainly driven by
the Rest of the World region (+89.5% CER).
Sales of Wayrilz (immune thrombocytopenia) amounted to €27 million, exclusively in the United States, following the marketing
approval obtained in August 2025.
Sales of Qfitlia (hemophilia A and B) reached €12 million, exclusively in the United States, the treatment having been approved in
March 2025.
48
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
Sales of Myqorzo (hypertrophic obstructive cardiomyopathy) amounted to €3 million, entirely in China, following the marketing
authorization obtained in January 2026.
rovadicitinib (myelofibrosis, no brand name in English) launched in China during the second quarter with sales anticipated to be
reported from Q3 2026 results.
Other main medicines
Lantus sales were €813 million (-3.8% CER) in the first half of 2026. In the United States, sales were down 6.6% CER. Revenue
declined by 2.7 % CER in Europe, and by 0.9 % CER in the Rest of the World region owing to the strategy of switching to Toujeo.
Toujeo sales rose by 7.5% CER to €729 million, driven by the United States (+14.3%) and Europe (+3.6%). Toujeo continues to
benefit from strong volume growth and increasing market share worldwide.
Plavix sales were down 4.4% CER at €440 million, reflecting a decline in the Rest of the World region, which represents the bulk
of sales (€398 million, -4.0 % CER).
Lovenox sales decreased by 19.2% CER to €364 million, reflecting the sustained impact of biosimilars.
Sales of Sarclisa (multiple myeloma) increased to €354 million (+33.0% CER), supported by strong growth in Europe (+30.1%
CER), largely fuelled by expanded use among newly diagnosed patients, and in the Rest of the World region (+60.8% CER), which
benefited from reimbursement and favorable commercial contracts.
In the first half of 2026, Praluent sales increased by 18.4% CER to €317 million, reflecting higher sales in Europe (+25.8% CER),
partially offset by a decline in the Rest of the World region (-8.6% CER).
Rezurock (chronic graft-versus-host disease, third-line) sales increased to €296 million in the first half of the year, up 18.3% CER.
This growth was driven by a strong performance in the Rest of the World region (+110.0% CER, primarily in China), while the
United States recorded growth of 5.5% CER and Europe 60.9% CER, benefitting from the conditional marketing authorization
granted by the European Commission on March 31, 2026.
Thymoglobulin sales rose by 8.5% CER to €257 million, primarily due to higher sales in the Rest of the World region, mainly in
China.
Aprovel sales were relatively stable at €218 million (+4.2% CER), mainly generated in the Rest of the World region (€184 million,
+7.5% CER).
Sales of Tzield/Teizeild (type 1 diabetes) reached €37 million (+34.5% CER), of which €32 million were generated in the United
States (up 25.9% CER). Launches have begun in Europe (€4 million) and the Rest of the World region (€1 million). Over 1,000
patients have now received treatment with Tzield/Teizeild.
Vaccines
In the first half of 2026, Vaccines sales were down 3.8% on a reported basis and down 1.1% CER at €2,443 million, due mainly to
lower sales of influenza and meningitis, travel, and endemic vaccines.
Sales of Polio/pertussis/Hib primary vaccines and boosters, including Heplisav-B rose by 2.8% CER to €1,364 million. Sales in the
United States (€487 million, +61.3% CER) increased thanks to the inclusion of newly acquired Heplisav-B to the portfolio. In the
Rest of the World region (€671 million), sales were down 17.2% CER, impacted by a decline in childbirths (mostly in China).
Meningitis, Travel and Endemics Vaccines sales decreased by 3.9% CER to €565 million, with a decline in sales in the United
States (€268 million, -11.0% CER) partially offset by the performance achieved in Europe (€118 million, +22.9% CER).
Beyfortus sales reached €392 million, up 13.2% CER. The moderate increase in US sales (+2.9% CER) was due to a high
comparative base resulting from increased inventory levels in the first half of 2025, as well as competitive pressure. Sales in
Europe (+2.4% CER ) and the Rest of the World region (+21.2% CER) benefited from ongoing geographical expansion of infant
protection, with Beyfortus now protecting infants in more than 45 countries.
Sales of Influenza and COVID-19 Vaccines reached €121 million, down 42.1% CER, mainly due to one-offs from late-season
immunizations in the US and Europe and lower sales in the Southern Hemisphere, with sales in the Rest of the World region down
34.3% CER at €72 million.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
49
Exhibit 99.2
2. Half-year management report
D.3.4. Net sales by geographical region
(€ million)
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Change on a Change at constant
reported basis
exchange rates
United States
11,633
9,535
+22.0%
+29.9%
Europe
4,304
4,144
+3.9%
+3.6%
Rest of the World
6,169
6,210
-0.7%
+1.9%
of which China
1,325
1,388
-4.5%
-3.5%
22,106
19,889
+11.1%
+15.7%
Total net sales
In the first half of 2026, net sales in the United States reached €11,633 million, up 22.0% on a reported basis and 29.9% at
constant exchange rates, driven by strong growth for Dupixent and pharma launches. Vaccines sales also posted a substantial
increase, of 16.8% CER, driven by strong growth in Polio/pertussis/Hib primary vaccines and boosters, including Heplisav-B.
In Europe, 2026 first-half net sales rose by 3.9% on a reported basis and 3.6% at constant exchange rates, to €4,304 million.
Growth was driven by Dupixent and launches, partially offset by lower sales of other main medicines.
In the Rest of the World region, first-half net sales were down 0.7% on a reported basis but up 1.9% at constant exchange rates at
€6,169 million. Sales were boosted by Dupixent, which returned to growth after a price adjustment in 2025, and by the three
drugs launched in China (Rezurock, Sarclisa, and Myqorzo). This was more than offset by declining sales of established drugs
(particularly Plavix) and a marked drop in sales of PPH vaccines due to the decrease in the birth rate in China.
D.4. Other income statement items
D.4.1. Other revenues
Other revenues decreased by 1.0% to €1,438 million in the first half of 2026 (versus €1,452 million in the first half of 2025).
The Other revenues line item includes VaxServe sales of non-Sanofi vaccines, amounting to €746 million (versus €842 million in
2025). In addition, other revenues included manufacturing and other services (€271 million); sales of Opella consumer health
products in certain markets (€270 million); royalties (€91 million), and sales of supplies to Opella, etc. (€60 million).
D.4.2. Gross profit
Gross profit for the first half of 2026 was €17,389 million, versus €15,460 million for the first half of 2025, a rise of 12.5%. This
increase includes a €210 million amortization charge arising from the remeasurement of inventories relating to the Blueprint and
Dynavax acquisitions and reported within Cost of sales. This was partially offset by reversals of past provisions for pre-launch
inventories amounting to over €200 million, following regulatory approval of Sarclisa SC.
Gross margin (the ratio of gross profit to net sales) also increased, reaching 78.7% in the first half of 2026 (versus 77.7% in the
first half of 2025).
In the first half of 2026, the business gross profit was €17,599 million and increased by 13.8% from €15,460 million in the first half
of 2025. Business gross profit is a non-IFRS indicator that fully excludes from gross profit under IFRS the effect of the release of
the fair value step-up to inventory that is recognised upon acquisition, amounting to €210 million for the first half of 2026 and nil
for the first half of 2025 (please refer to D.2. reconciling Net income attributable to equity holders of Sanofi to “Business net
income”).
D.4.3. Research and development expenses
Research and development expenses (R&D expenses) in the first half of 2026 totaled €3,980 million, versus €3,717 million in
the first half of 2025, a year-on-year increase of 7.1%. The increase includes more than €200 million of wind-down costs from
decisions made on the pipeline.
R&D expenses represented 18.0% of net sales, compared with 18.7% in the first half of 2025.
D.4.4. Selling and general expenses
Selling and general expenses amounted to €4,792 million in the first half of 2026 (21.7% of net sales), versus €4,506 million in
the first half of 2025 (22.7% of net sales). The year-on-year increase of 6.3% was elevated by the consolidation of recent
acquisitions: Blueprint (July 2025) and Dynavax (February 2026).
The ratio of selling and general expenses to net sales was 1.0 percentage point lower than in the first half of 2025.
50
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
D.4.5. Other operating income and expenses
Other operating income amounted to €800 million in the first half of 2026 (versus €533 million in the first half of 2025), and
Other operating expenses to €3,436 million (versus €2,476 million in the first half of 2025). Overall, Other operating income
and expenses represented a net expense of €2,636 million in the first half of 2026, compared with a net expense of €1,943
million in the first half of 2025, as shown in the table below.
June 30, 2026
(6 months)
June 30, 2025
(6 months)
Net gains / (losses) on disposals of operating assets or businesses
241
344
Amvuttra licensing income
398
120
Other
161
69
800
533
(3,486)
(2,475)
(€ million)
Total other operating income
Regeneron alliance:
(i) (Profit)/loss sharing
(ii) Additional profit share for development cost from Regeneron
594
494
(iii) Selling expense reimbursements to Regeneron
(336)
(346)
Other
(208)
(149)
(3,436)
(2,476)
Total other operating expenses
D.4.6. Amortization of intangible assets
Amortization charged against intangible assets in the first half of 2026 amounted to €1,087 million, versus €777 million in the first
half of 2025. The increase is mainly related to amortization of intangible assets recognized in the first half of 2026 following the
Blueprint and Dynavax acquisitions.
D.4.7. Impairment of intangible assets
The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment
losses of €1,031 million in the first half of 2026, mainly comprising a €952 million impairment loss taken against the amlitelimab
asset, corresponding to the entire carrying amount of this intangible asset.
D.4.8. Fair value remeasurement of contingent consideration
Fair value remeasurements of contingent consideration assets and liabilities relating to business combinations (recognized in
accordance with IFRS 3) represented a net expense of €37 million in the first half of 2026, versus a net expense of €61 million in
the first half of 2025.
D.4.9. Restructuring costs and similar items
Restructuring costs and similar items amounted to a charge of €563 million in the first half of 2026, compared with a charge
of €430 million in the first half of 2025. The charge recognized in the first half 2026 mainly includes €284 million of employeerelated expenses (compared with an expense of €201 million for the first half of 2025) and €179 million of charges, gains or losses
on assets (compared with an expense of €109 million for the first half of 2025).
D.4.10. Other gains and losses, and litigation
For the first half of 2026, Other gains and losses, and litigation represents a charge of €95 million mainly related to major
litigation, compared with a charge of €57 million in the first half of 2025.
D.4.11. Operating income
Operating income amounted to €3,168 million in the first half of 2026, versus €3,759 million in the first half of 2025. The yearon-year change was mainly due to the increase in Other operating expenses.
D.4.12. Financial income and expenses
Net financial expenses were €328 million in the first half of 2026, €151 million higher than the 2025 first-half figure of €177
million. The 2026 first-half figure includes a financial expense of €146 million (€50 million for the first half of 2025) arising from
the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United
States.
Our cost of net debt (see the definition in Section D.7., “Consolidated balance sheet” below) was €135 million in the first half of
2026, compared with €57 million in the first half of 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
51
Exhibit 99.2
2. Half-year management report
D.4.13. Income before tax and investments accounted for using the equity method
Income before tax and investments accounted for using the equity method for the first half of 2026 was €2,840 million,
versus €3,582 million for the first half of 2025.
D.4.14. Income tax expense
Income tax expense totaled €871 million in the first half of 2026, versus €711 million in the first half of 2025, giving an effective
tax rate (based on consolidated net income) of 30.6%, versus 19.8% in the first half of 2025. The increase in the effective tax rate
was mainly due to the non-deductibility of current year impairment losses taken against the amlitelimab intangible asset.
The effective tax rate on our “Business net income”(1) is a non-IFRS financial measure. It is calculated on the basis of business
operating income, minus net financial expenses and before (i) the share of profit/loss from investments accounted for using the
equity method and (ii) net income attributable to non-controlling interests. We believe the presentation of this measure, used by
our management, is also useful for investors as it provides a means of analyzing the effective tax cost of our current business
activities. It should not be seen as a substitute for the effective tax rate based on consolidated net income.
When calculated on business net income, our effective tax rate was 21.8% in the first half of 2026, compared with 21.0% in the
first half of 2025 and 19.9% for 2025 as a whole. The main factors include (i) movements in deferred tax assets related to the
amlitelimab intangible asset and (ii) the year-on-year change arising from the full effects of the 2026 portion of the temporary
exceptional surcharge in France based on 2025 taxable profits.
D.4.15. Share of profit/(loss) from investments accounted for using the equity method
Share of profit/(loss) from investments accounted for using the equity method showed net income of €2 million for the first
half of 2026 (including a net loss of €39 million for Sanofi’s share of losses from the associate OPAL JV Co), versus net income of
€85 million for the first half of 2025 (including net income of €11 million for Sanofi’s share of profits from the associate OPAL JV
Co for the period from May 1, 2025 through June 30, 2025).
D.4.16. Net income from continuing operations
Net income from continuing operations amounted to €1,971 million in the first half of 2026, compared with €2,956 million in
the first half of 2025.
D.4.17. Net income from discontinued operations
In the first half of 2026, Net income from discontinued operations amounted to €26 million, mainly comprising the impact of
the finalization of the Opella completion accounts, versus €2,881 million in the first half of 2025. The 2025 first-half figure
included (i) the net income of Opella until the date of loss of control and (ii) a net gain of €2,693 million resulting from the
divestment of Opella as of the date of loss of control.
D.4.18. Net income
Net income amounted to €1,997 million in the first half of 2026, versus €5,837 million in the first half of 2025; the 2025 first-half
figure included the €2,693 million gain on the divestment of Opella.
D.4.19. Net income attributable to non-controlling interests
Net income attributable to non-controlling interests for the first half of 2026 was €40 million, against €25 million for the first
half of 2025.
D.4.20. Net income attributable to equity holders of Sanofi
Net income attributable to equity holders of Sanofi amounted to €1,957 million in the first half of 2026, versus €5,812 million in
the first half of 2025.
Basic earnings per share (EPS) was €1.63, compared with €4.74 for the first half of 2025, based on an average number of shares
outstanding of 1,200.4 million for the first half of 2026 and 1,225.5 million for the first half of 2025. Diluted earnings per share was
€1.62, versus €4.72 for the first half of 2025, based on an average number of shares after dilution of 1,205.5 million for the first
half of 2026 and 1,230.7 million for the first half of 2025.
D.5. Segment results
For the Biopharma segment, business operating income (see definition and details in note B.21.1 to the condensed half-year
consolidated financial statements) amounted to €6,258 million in the first half of 2026, compared with €5,363 million in the first
half of 2025, an increase of 16.7%. It represents 28.3% of sales, compared with 27.0% in the first half of 2025.
(1)
See definition in section D.2., “Business net income”.
52
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
D.6. Consolidated statements of cash flows
Summarized consolidated statements of cash flows:
(€ million) (a)
Net cash provided by/(used in) continuing operating activities
June 30, 2026
(6 months)
June 30, 2025
(6 months)
4,643
3,367
—
188
Net cash provided by/(used in) operating activities
4,643
3,555
Net cash provided by/(used in) continuing investing activities
(2,423)
(1,979)
—
(36)
(220)
10,742
Net cash provided by/(used in) operating activities of the discontinued Opella business
Net cash provided by/(used in) investing activities of the discontinued Opella business
Net cash inflow/(outflow) from the Opella transaction
(b)
Net cash provided by/(used in) investing activities
(2,643)
8,727
Net cash provided by/(used in) continuing financing activities
(3,332)
(4,441)
—
(48)
Net cash provided by/(used in) financing activities of the discontinued Opella business
Net cash provided by/(used in) financing activities
(3,332)
(4,489)
Impact of exchange rates on cash and cash equivalents
19
(42)
Cash and cash equivalents reclassified as “Assets held for sale” as of December 31, 2024
—
167
(1,313)
7,918
Net change in cash and cash equivalents
Cash and cash equivalents, beginning of period (c)
7,663
7,441
Cash and cash equivalents, end of period
6,350
15,359
(a) Opella's cash flows are presented separately in accordance with IFRS 5 (Non-current Assets Held for Sale and Discontinued Operations).
(b) For the six months ended June 30, 2025, this amount includes €(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.
(c) Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.
Net cash provided by/(used in) continuing operating activities represented a net cash inflow of €4,643 million in the first half
of 2026, against €3,367 million in the first half of 2025. This increase was mainly driven by a higher level of operating cash flow
before changes in working capital (€5,233 million in the first half of 2026 versus €3,980 million in the first half of 2025).
Working capital requirements decreased by €590 million in the first half of 2026, versus a decrease of €613 million in the first
half of 2025.
Net cash provided by/(used in) continuing investing activities represented a net cash outflow of €2,423 million in the first half
of 2026. The principal cash outflow in the first half of 2026 was the €1,403 million arising from the acquisition of Dynavax (see
Note B.1.1.). That compares with a net cash outflow of €1,979 million in the first half of 2025, including the impact of the
acquisition of Dren-0201, Inc. for €539 million.
Acquisitions of property, plant and equipment and intangible assets totaled €1,296 million, versus €1,420 million in the first half of
2025. There were €882 million of acquisitions of property, plant and equipment (versus €845 million in the first half of 2025),
corresponding primarily to investments in industrial facilities. Acquisitions of intangible assets (€414 million, versus €575 million in
the first half of 2025) mainly comprised contractual payments for intangible rights, primarily under license and collaboration
agreements.
Proceeds from disposals net of tax (excluding disposals of consolidated entities and investments accounted for using the equity
method) amounted to €424 million in the first half of 2026, compared with €434 million for the first half of 2025, and related
mainly to divestments of assets and operations relating to portfolio streamlining and to disposals of equity and debt instruments.
Net cash provided by/(used in) continuing financing activities represented a net cash outflow of €3,332 million in the first
half of 2026, compared with a net outflow of €4,441 million in the first half of 2025. The 2026 first-half figure includes (i) the
dividend payout to our shareholders of €4,923 million (versus €4,772 million in the first half of 2025); (ii) €2,607 million of net
external debt contracted (versus net external debt contracted of €4,332 million in the first half of 2025); and (iii) movements in
Sanofi’s share capital, including purchases of treasury shares and the related tax effects of €1,009 million, versus €4,003 million
in the first half of 2025.
Net cash flows from the Opella transaction represented a net cash outflow of €220 million in the first half of 2026, versus a net
cash inflow of €10,742 million in the first half of 2025.
The net change in cash and cash equivalents in the first half of 2026 was a decrease of €1,313 million, compared with an
increase of €7,918 million in the first half of 2025.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
53
Exhibit 99.2
2. Half-year management report
“Free cash flow” is a non-IFRS financial measure which is reviewed by our management, and which we believe provides useful
information to measure the net cash generated from the Company’s operations that is available for strategic investments(1) (net
of divestments(1)), for debt repayment, and for payments to shareholders. “Free cash flow” is determined from business net
income(2) after adding back (in the case of expenses and losses) or deducting (in the case of income and gains) the following
items: depreciation, amortization and impairment, share of undistributed earnings from investments accounted for using the
equity method, gains & losses on disposals of non-current assets, net change in provisions (including pensions and other postemployment benefits), deferred taxes, share-based payment expense and other non-cash items. It also includes net changes in
working capital, capital expenditures and other asset acquisitions(3) net of disposal proceeds(3) and payments related to
restructuring and similar items. “Free cash flow” is not defined by IFRS, and is not a substitute for Net cash provided by/(used
in) operating activities as reported under IFRS. Management recognizes that the term “Free cash flow” may be interpreted
differently by other companies and under different circumstances.
The table below sets forth a reconciliation between Net cash provided by/(used in) operating activities and “Free cash flow”:
(€ million)
Net cash provided by/(used in) operating activities(a)
Net cash provided by/(used in) operating activities of the discontinued Opella business
June 30, 2026
(6 months)
June 30, 2025
(6 months)
4,643
3,555
—
(188)
Acquisitions of property, plant and equipment and software
(967)
(873)
Acquisitions of intangible assets, equity interests and other non-current financial assets(b)
(534)
(986)
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets,
net of tax(b)
361
434
Repayment of lease liabilities
(147)
(124)
Other items (c)
368
640
3,724
2,458
Free cash flow (non-IFRS) (d)
(a) Most directly comparable IFRS measure to free cash flow.
(b) Not exceeding a cap of €500 million per transaction.
(c) This line item includes cash outflows from major litigation not included in “Free cash flow”, in particular Plavix Hawaii in 2025.
(d) Non-IFRS financial measure (see definition above).
D.7. Consolidated balance sheet
Total assets were €129,060 million as of June 30, 2026, versus €126,805 million as of December 31, 2025, representing an
increase of €2,255 million.
Net debt was €15,513 million as of June 30, 2026, versus €11,008 million as of December 31, 2025. We believe the presentation of
this non-IFRS financial measure, which is reviewed by our management, provides useful information to measure our overall
liquidity and capital resources. We define “net debt” as (i) the sum total of short-term debt, long-term debt, and interest rate
derivatives and currency derivatives used to manage debt, minus (ii) the sum total of cash and cash equivalents and interest rate
derivatives and currency derivatives used to manage cash and cash equivalents.
(€ million)
June 30, 2026
December 31, 2025
Long-term debt
14,646
14,248
Short-term debt and current portion of long-term debt
7,026
4,342
221
112
Total debt (IFRS)
21,893
18,702
Cash and cash equivalents
(6,350)
(7,657)
Interest rate and currency derivatives used to manage debt
Interest rate and currency derivatives used to manage cash and cash equivalents
(30)
(37)
Net debt (a) (non-IFRS)
15,513
11,008
Total equity
69,567
71,710
Gearing ratio (non-IFRS)
22.3 %
15.4 %
(a) Net debt does not include lease liabilities, which amounted to €1,904 million as of June 30, 2026 and €1,739 million as of December 31, 2025.
To assess our financing risk, we use the “gearing ratio”, another non-IFRS financial measure. This ratio (which we define as the
ratio of net debt to total equity) rose from 15.4% as of December 31, 2025 to 22.3% as of June 30, 2026. Analyses of our debt as
of June 30, 2026 and December 31, 2025 are provided in Note B.9. to our condensed half-year consolidated financial
statements.
Because our “net debt” and “gearing ratio” are not standardized measures, they may not be directly comparable with the
non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non(1)
Above a cap of €500 million per transaction.
Non-IFRS financial measure, as defined in “Business net income” above.
(3)
Not exceeding a cap of €500 million per transaction.
(2)
54
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
IFRS measures by management in setting goals and measuring performance, these measures have no standardized meaning
prescribed by IFRS.
We expect that the future cash flows generated by our operating activities will be sufficient to repay our debt. The financing
arrangements in place as of June 30, 2026 at the Sanofi parent company level are not subject to covenants regarding financial
ratios and do not contain any clauses linking credit spreads or fees to Sanofi’s credit rating.
Other key movements in the balance sheet are described below.
Total equity was €69,567 million as of June 30, 2026, versus €71,710 million as of December 31, 2025. The net change reflects
the following principal factors:
• an increase representing our net income for the first half of 2026 (€1,997 million);
• an increase of €1,802 million due to currency translation differences arising on the financial statements of foreign subsidiaries,
mainly due to movements in the US dollar;
• a decrease representing the dividend payout to our shareholders of €4,923 million; and
• the repurchase by Sanofi of 12,571,455 of its own shares during the first half of 2026 for a total amount of €1,003 million, plus
€3 million of related tax payments.
As of June 30, 2026 we held 16.03 million of our own shares, recorded as a deduction from equity and representing 1.320% of our
share capital.
Goodwill and Other intangible assets (€68,313 million in total) increased by €752 million, due mainly to the Dynavax acquisition
and the impact of exchange rates (particularly the fluctuation in the US dollar), partly offset by amortization and impairment
recognized on other intangible assets during the period.
Investments accounted for using the equity method (€3,207 million) decreased by €52 million.
Other non-current assets (€4,732 million) increased by €368 million.
Net deferred tax assets were €7,210 million as of June 30, 2026, compared with €6,942 million as of December 31, 2025, an
increase of €268 million.
Non-current provisions and other non-current liabilities (€6,848 million) were €145 million higher than at December 31, 2025.
Liabilities related to business combinations and to non-controlling interests (€652 million) increased by €67 million.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
55
Exhibit 99.2
2. Half-year management report
E/ Risk factors and related party transactions
E.1. Risk factors
The main risk factors to which Sanofi is exposed are described in the 2025 Form 20-F for the year ended December 31, 2025,
filed with the US Securities and Exchange Commission on February 17, 2026(1).
Any of those risks, and others that we may not yet have identified, could materialize during the second half of 2026 or during
subsequent periods, and could cause actual results to differ materially from those described elsewhere in this report.
E.2. Related party transactions
Our principal related parties are defined in Note D.33. to our consolidated financial statements included in the 2025 Form 20-F
(page F-93)(1).
Note B.5. to our condensed half-year consolidated financial statements provides a description of the main transactions and
balances for the six months ended June 30, 2026 with equity-accounted entities that qualify as related parties.
Sanofi did not enter into any transactions with key management personnel during the first half of 2026.
Financial relations with the Group’s principal shareholders fall within the ordinary course of business and were immaterial in the
first half of 2026.
(1)
Available on our corporate website: www.sanofi.com.
56
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
F/ Outlook
In 2026, Sanofi net sales are now expected to grow by around 10% at constant exchange rates (1) (CER). Business earnings per
share (2) (Business EPS) is expected to grow slightly faster than sales.
Applying July 2026 average currency exchange rates, currency impacts are estimated at approximately -1% on sales and at
approximately -2% on Business EPS.
Full-year business net income(1) for 2025 was €9,555 million, resulting in Business earnings per share of €7.83.
This guidance was prepared on a basis comparable with that used to prepare our historical financial information, and in
accordance with Sanofi accounting policies. It was also prepared on the basis of assumptions established by Sanofi and its
subsidiaries, including but not limited to:
•
•
•
•
•
•
•
trends in the competitive environment, in terms of innovative products and launches of generics;
respect for our intellectual property rights;
progress on our research and development programs;
the impact of, and progress on, our operating cost containment policy;
trends in exchange rates and interest rates;
integration of the contribution from acquisitions; and
the average number of shares outstanding.
Some of the above information, estimates and assumptions are derived from or rely on, in full or in part, judgments and decisions
made by Sanofi management which may change or be amended in future.
(1)
(2)
Non-IFRS financial measure. For a definition, see Section D.3., “Net Sales” above.
Non-IFRS financial measure. For a definition, see Section D.2., “Business net income” above.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
57
Exhibit 99.2
2. Half-year management report
Forward-looking statements
This document contains forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to
future financial results, events, operations, services, product development and potential, and statements regarding future
performance. Words such as “believe”, “anticipate”, “can”, “contemplate”, “could”, “plan”, “expect”, “intend”, “is designed to”,
“may”, “might”, “plan”, “potential”, “objective” “target”, “estimate”, “project”, “predict”, “forecast”, “ambition”, “guideline”,
“should”, “will”, “estimates”, “plans” or the negative of these and similar expressions are intended to identify forward-looking
statements but are not the exclusive means of identifying such statements. Forward-looking statements are generally identified
by the words “expects”, “anticipates”, “may”, “is considering”, “believes”, “intends”, “envisages”, “aims”, “plans”, “is designed to”,
“could”, “forecasts”, “predicts”, “potential”, “objective”, “estimates”, “projects”, “is programming”, “is likely to” and “wants” or the
negative thereof, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that
could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the
forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical
data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether
and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their
decisions regarding labelling and other matters that could affect the availability or commercial potential of such product
candidates, the fact that product candidates if approved may not be commercially successful, the future approval and
commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crisis
may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them,
as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the U.S. Securities and Exchange Commission (SEC) and the French Autorité des
marchés financiers (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s Annual Report on Form 20-F for the year ended December 31, 2025. For an update on
litigation, refer to Note B.14. “Legal and arbitration proceedings” to our condensed half-year consolidated financial statements
for the six months ended June 30, 2026, and to section “A.3.2. Legal and arbitration proceedings”, and section “E/ Risk factors
and related party transactions”, of this half-year management report.
With respect to any sustainability or environmental, social and governance (ESG)-related information contained herein, in light of
the significant uncertainties inherent in such statements and other related information contained herein, investors should not
regard these statements as a representation or warranty by Sanofi or any other person that Sanofi will achieve its goals,
objectives, aspirations, metrics, plans or targets in any specified time frame or at all, including with respect to ESG and
sustainability matters, and such statements and other information are dependent on future market factors, such as customer
demand, continued technological progress, policy support and timely rule-making or continuation of government incentives and
funding, and are forward-looking statements. Sanofi’s ability to achieve goals, objectives, aspirations, metrics, plans or targets in
any specified time frame or at all, including with respect to ESG and sustainability matters, is subject to other conditions and
considerations, both within and outside Sanofi’s control, that may affect its ability to meet such goals, objectives, aspirations,
metrics, plans or targets, and/or put in place the initiatives required to meet them. Such conditions and considerations include
but are not limited to the risk factors described above. In addition, historical, current, and forward-looking environmental and
other ESG or sustainability-related statements may be based on standards for measuring progress that are still developing,
internal controls and processes that continue to evolve, and assumptions that are subject to change in the future, including
future laws and rulemaking. Sanofi plans to continue to evaluate its goals, objectives, aspirations, metrics, plans and targets and
its approach to them and may make adjustments as it deems necessary in light of such considerations.
Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements.
All trademarks mentioned in this document are protected and are either trademarks owned by Sanofi and/or its subsidiaries, or
trademarks licensed to Sanofi and/or its subsidiaries, or trademarks owned by third parties (including Regeneron and Sobi).
58
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
2. Half-year management report
G/ Appendix - research and development pipeline
R&D Pipeline
Registration
Name
Description
Indication
venglustat
Oral GCS inhibitor
Gaucher disease type 3 (US, EU, JP)
Sarclisa
CD38 mAb subcutaneous
Multiple myeloma (CN)
Fluzone HD
Multivalent inactivated vaccine
Influenza 50 years+ (US, EU)
SP0087
Vero cell vaccine
Rabies (EU)
Phase 3
Name
Description
Indication
Immunology
Name
Description
Indication
Rare diseases
Dupixent (a)
IL4R mAb
Chronic pruritus of
unknown origin
Nexviazyme
Enzyme replacement
therapy
Infantile-onset Pompe
disease (US)
duvakitug (b)
TL1A mAb
Crohn’s disease
Ulcerative colitis
elenestinib
D816V-mutated KIT
inhibitor
Indolent/smoldering
systemic mastocytosis
lunsekimig
IL13×TSLP
Nanobody® VHH
Chronic obstructive
pulmonary disease
fitusiran
RNAi targeting antithrombin
Hemophilia A and B (EU,
JP)
Rezurock
ROCK2 inhibitor
Chronic lung allograft
dysfunction
Wayrilz
BTK inhibitor
Sickle cell disease
IgG4-related disease
Warm autoimmune
hemolytic anemia
frexalimab
CD40L mAb
Kidney transplant rejection
frexalimab (c)
CD40L mAb
Relapsing MS
Non-relapsing secondary
progressive MS
CD38 mAb
NDMM, TE (HD7)
NDMM, TE (IsKia)
Smoldering MM (ITHACA)
riliprubart
C1s mAb
IVIg-treated CIDP
Vero cell vaccine
Yellow fever
21-valent conjugate
vaccine
Pneumococcal disease
(children)
Neurology
Oncology
Sarclisa
Vaccines
SP0218
SP0202
(d)
Collaborations: (a) Regeneron; (b) Teva Pharmaceuticals; (c) ImmuNext; (d) SK bioscience.
Abbreviations:
BTK: Bruton’s tyrosine kinase – CD: Cluster of differentiation – C1s: Complement component 1s – CIDP: Chronic inflammatory demyelinating polyneuropathy – CN: China
–EU: Europe – GCS: Glucosylceramide synthase – HD: High dose – IgG4: Immunoglobulin G4 – IL: Interleukin – IVIg: Intravenous immunoglobulin – JP: Japan – mAb:
Monoclonal antibody - MM: Multiple myeloma - MS: Multiple sclerosis - NDMM: Newly diagnosed multiple myeloma - RNAi: RNA interference - ROCK2: Rho Associated
coiled-coil containing protein kinase 2 – TE: Transplant eligible – TL1A: Tumor necrosis factor-like cytokine 1A – TSLP: Thymic stromal lymphopoietin
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
59
Exhibit 99.2
2. Half-year management report
Phase 2
Name
Description
Indication
Description
Indication
brivekimig
TNFa×OX40L
Nanobody® VHH
Crohn’s disease
Hidradenitis suppurativa
Ulcerative colitis
Type 1 diabetes, stage 3
Wayrilz
BTK inhibitor
Graves' disease
frexalimab(a)
CD40L mAb
Type 1 diabetes, stage 3
efdoralprin alfa
AAT fusion protein
Alpha-1 antitrypsin
deficiency emphysema
lunsekimig
IL13×TSLP Nanobody®
VHH
Asthma
Asthma, high-risk
Chronic rhinosinusitis with
nasal polyps
frexalimab
rilzabrutinib
brivekimig
CD40L mAb
BTK inhibitor
TNFa×OX40L
Nanobody® VHH
Focal segmental
glomerulosclerosis/
minimal change disease
SAR449028
Wild-type KIT inhibitor
Chronic urticaria
Immunology
SAR444336
SAR445399
(1)
Rare diseases
Non-beta IL2 Synthorin Microscopic colitis
Oncology
IL1R3 mAb
SAR445877
PD1×IL15 fusion protein
Solid tumors
Sarclisa
CD38 mAb
Relapsed/refractory
multiple myeloma in
combination
mRNA vaccine
RSV+hMPV (older adults)
Hidradenitis suppurativa
Neurology
SAR402663
Name
Vaccines
sFLT01 AAV gene
therapy
Wet age-related macular
degeneration
SP0256
SP0268
mRNA vaccine
Acne
SP0289
mRNA vaccine
Influenza H5 pandemic
SP0335
Inactivated adjuvanted
vaccine
Influenza H5 pandemic
Name
Description
Indication
Phase 1
Name
Description
Indication
Oncology
Immunology
SAR446422
CD28×OX40 bispecific
Ab
Inflammatory indication
SAR445953 (b)
CEACAM5-Topo1 ADC
Colorectal cancer
SAR448501
CD20 bispecific mAb
Inflammatory indication
SAR446523
GPRC5D mAb
Relapsed/refractory
multiple myeloma
SAR447971
IRAK4 degrader
Hidradenitis suppurativa
SAR449336
Pan KRAS inhibitor
Colorectal cancer
Neurology
Vaccines
SAR446597
Bb×C1s AAV gene
therapy
Geographic atrophy in dry
age-related macular
degeneration
SP0287
Fluzone HD+Nuvaxovid
Influenza+COVID-19
SAR448851
TREM2 agonist
Alzheimer’s disease
SP0287
Flublok+Nuvaxovid
Influenza+COVID-19
SP0291
mRNA vaccine
RSV+hMPV+PIV3 (older
adults)
SP0269
mRNA vaccine
Chlamydia
SP0340
Subunit vaccine
RSV+hMPV (older adults)
SP0341
Subunit vaccine
RSV+hMPV+PIV3 (older
adults)
SP0342
Subunit adjuvanted
vaccine
Shingles
Rare diseases
SAR446268
DMPK AAV gene
therapy
Myotonic dystrophy type 1
(1) Also known as MAB212, in-licensed from MAB Discovery.
Collaborations: (a) ImmuNext; (b) Pfizer
Abbreviations:
AAT: Alpha–1 antitrypsin – AAV: Adeno-associated virus – Ab: Antibody – ADC: Antibody-drug conjugate – Bb: Factor Bb – BTK: Bruton’s tyrosine kinase –
C1s: Complement component 1s – CD: Cluster of differentiation – CEACAM5: Carcinoembryonic antigen cell adhesion molecule 5 – DMPK: dystrophia
myotonica protein kinase 1 – GPRC5D: G-protein-coupled receptor class 5 member D – H5: hemagglutinin 5 - hMPV: human Metapneumovirus - JAK:
Janus kinase – KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog - IL: Interleukin – IL1R3: Interleukin-1 receptor 3 – mAb: Monoclonal antibody –
mRNA: messenger RNA – PD1: Programmed death protein 1 – PIV3: Parainfluenza virus type 3 – RSV: Respiratory syncytial virus – TNFa: Tumor necrosis
factor alpha – TNFR1: Tumor necrosis factor receptor 1 – Topo1: Topoisomerase - TREM2: triggering receptor expressed on myeloid cells 2 – TSLP: Thymic
stromal lymphopoietin
60
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Exhibit 99.2
3. Statutory auditors’ review report on the half-yearly financial information
-
Statutory auditors’ review report on
the half-yearly financial information
Period from January 1 to June 30, 2026
To the Shareholders,
In compliance with the assignment entrusted to us by your Annual General Meetings and in accordance with the requirements of
article L. 451-1-2 III of the French Monetary and Financial Code ("Code monétaire et financier"), we hereby report to you on:
• the review of the accompanying (condensed) half-yearly consolidated financial statements of Sanofi, for the period from
January 1, 2026 to June 30, 2026;
• the verification of the information presented in the half-yearly management report.
These condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to
express a conclusion on these financial statements based on our review.
-
Conclusion on the financial statements
We conducted our review in accordance with professional standards applicable in France.
A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and
accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit
conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain
assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not
express an audit opinion.
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly
consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 – standard of the IFRSs as
adopted by the European Union applicable to interim financial information.
-
Specific verification
We have also verified the information presented in the half-yearly management report on the condensed half-yearly
consolidated financial statements subject to our review.
We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial
statements.
Neuilly-sur-Seine and Levallois-Perret, July 30 2026.
The statutory auditors
French original signed by
PricewaterhouseCoopers Audit
Anne-Claire Ferrié
Amélie Graffan
Forvis Mazars SA
Loïc Wallaert
Ariane Mignon
This is a free translation into English of the statutory auditors’ review report on the half-yearly financial information issued in French and is provided
solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the
Group’s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional
standards applicable in France.
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
61
Exhibit 99.2
4. Responsibility statement of the certifying officer: half-year financial report
- Responsibility statement of the
certifying officer: half-year financial
report
“I hereby certify that, to the best of my knowledge, the condensed half-year consolidated financial statements have been
prepared in accordance with the applicable accounting standards and give a true and fair view of the assets and liabilities,
financial position and net income of the Company and the entities included in the scope of consolidation, and that the half-year
management report starting on page 35 provides an accurate overview of the significant events of the first six months of the
financial year with their impact on the half-year consolidated financial statements, together with the major transactions with
related parties and a description of the main risks and uncertainties for the remaining six months of the financial year.”
Paris, July 30, 2026
Belén Garijo
Chief Executive Officer
62
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
Notes
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................................
SANOFI
HALF-YEAR FINANCIAL REPORT 2026
63
www.sanofi.com
46 Avenue de la Grande Armée 75017
Paris